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DIAGNOSTIC IMMUNOHISTOCHEMISTRY WITH TISSUE 
MICROARRAY TECHNIQUE – A PILOT STUDY ON NON 
HODGKIN LYMPHOMA 
                                                                    
      Abstract: Non-Hodgkin lymphoma (NHL) is a collective term for a 
heterogeneous group of lymphoproliferative malignancies with differing 
patterns of behaviour and responses to treatment. Incidence of lymphoma has 
doubled in the past 4 decades and continues to increase. In the context of 
lymphomas, immunohistochemistry is used to classify, sub-classify and 
predict prognosis of several classes of lymphomas. Tissue microarray 
facilitates the analysis of molecular alterations in thousands of tissue 
specimens in a massively parallel fashion. This study was conducted in 
Department of pathology, Tirunelveli medical college in which tissue micro 
array was prepared using manual method from lymph nodes of 21 cases 
among which 20 were diagnosed as Non-Hodgkin lymphoma by 
histomorphology. All the cases were subjected for immunohistochemical 
analysis using CD3, CD20, CD5, and CD10 from which 19 cases were taken 
for classification and analysis based on recent WHO classification of 
lymphomas and leukemias.  
 
Key words: Non Hodgkin lymphoma, CD, Immunohistochemistry, Lymph 
node, Tissue microarray, WHO. 
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AIM & OBJECTIVES 
 
 To apply a panel of basic IHC markers for the diagnosis and 
classification of Non Hodgkin lymphoma. 
 To standardize the manual tissue microarray technique. 
 To assess the efficacy and standardisation of Immunohistochemistry 
using tissue microarray technique. 
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INTRODUCTION 
 
Lymphoid neoplasms include a diverse group of tumors of B-cell, T-
cell, and NK-cell origin. In many instances the phenotype of the neoplastic 
cell closely resembles that of a particular stage of normal lymphocyte 
differentiation. Lymphomas are ranked 6
th
among all cancers, worldwide 
(1)
. 
Incidence of lymphoma has doubled in the past 4 decades and continues to 
increase. Non-Hodgkin lymphoma (NHL) is a collective term for a 
heterogeneous group of lymphoproliferative malignancies with differing 
patterns of behaviour and responses to treatment. Non Hodgkin lymphoma 
is the fifth most common cancer in the world with an upsurge of incidence 
in India. Compared with Hodgkin disease, NHL is much less predictable 
and has a far greater predilection to disseminate to extranodal sites. The 
prognosis depends on the histologic type, stage, and treatment.  
             Immunohistochemistry (IHC) is a method for localising specific 
antigens in tissues or cells based on antigen-antibody recognition. It seeks to 
exploit the specificity provided by the binding of an antibody with its 
antigen at a light microscopic level. Immunohistochemistry is applied in 
three circumstances: to completely phenotype the abnormal population of 
cells, to further characterize the abnormal population identified by flow 
cytometry or to screen reactive tissue for a subtle abnormal population of 
cells. In the context of lymphomas, immunohistochemistry is not only used 
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in the aforementioned circumstances, but also to classify, sub-classify and 
predict prognosis of several classes of lymphomas.  
          Since its discovery by Battifora in 1986, tissue microarray is 
becoming a useful tool for research and quality control in 
immunohistochemistry. Tissue microarray facilitates the analysis of 
molecular alterations in thousands of tissue specimens in a massively 
parallel fashion. Since the advent of high-throughput techniques like cDNA 
microarrays, serial analysis of gene expression (SAGE) and proteomics, the 
biomedical research field has changed fundamentally. Since, no single 
antigen is lineage or lymphoma specific, a panel of immunohistochemical 
markers are to be used. Hence, the use of tissue microarray allows rapid and 
efficient analysis of large number of paraffin-embedded lymphoma tissues 
by a panel of markers under standardized immunohistochemical technique. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review of Literature 
4 
 
REVIEW OF LITERATURE 
 
LYMPH NODE 
Lymphoid organs constitute important component of our body. They 
are classified as central and peripheral lymphoid organs. The organs in 
which the lymphoid cells are primarily produced constitute the central 
lymphoid tissues while peripheral lymphoid organs are those in which the 
lymphoid cell differentiates, matures and processes the antigen. Bone 
marrow and thymus are the central lymphoid organs from which the 
lymphoid cells (B-lymphocytes and T-lymphocytes) are produced. Lymph 
nodes, spleen, MALT (Mucosa associated lymphoid tissue) constitutes 
peripheral lymphoid organs. 
Among all the other peripheral lymphoid organs, lymph nodes are 
considered the most important because they actively participate in immune 
response. Lymph nodes are organised collection of lymphoid cells 
surrounded by a capsule and located in regions where they drain the 
lymphatic vessels. These include cervical, axillary, abdominal, pelvic and 
inguinal group of lymph nodes. They are bean shaped organs composed of 
dense collection of lymphoid cells. Normally, the lymph node measures 
about 2 to 20 mm with an average of 15mm in its longest dimension.
(2,3)  
Lymph nodes are connected to the general circulation by means of 
afferent and efferent lymphatic vessels. Normally, lymph nodes are non 
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palpable, soft, grey-pink and homogenous. They become palpable as a result 
of intense immune response, neoplastic transformation or metastatic deposit.  
The diameter of lymph node greater than 3cm with nodular whitish cut 
surface and firm consistency are the features suggestive of neoplastic 
transformation or metastatic deposit. 
           The characteristic features of lymph node architecture varies 
according to age and site based upon the exposure of lymphoid cells to 
different antigens. Normally, lymph nodes draining the head and neck 
region including the cervical and axillary lymph nodes show numerous 
lymphoid follicles with reactive germinal centres which are due to 
secondary antigenic stimulation. But, lymph nodes such as mesenteric nodes 
possess wide medullary cords and sinuses. The count of peripheral lymph 
nodes also varies significantly with no nodes in newborn, numerous in 
younger age groups and more numerous in the elderly
(4)
. 
            Lymph nodes are organs with complex architecture where a variety 
of cell population are arranged in distinct compartments. This provides a 
favourable environment for interaction and processing of foreign antigens 
resulting in effective immune response. Hence, lymph nodes are not only 
involved in mechanical filtration of foreign bodies through the lymphatic 
vessels but also play a very important role in recognition and processing of 
antigen. 
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          The anatomy of lymph node includes cortex, medulla and para-
cortical area which are formed by lymphoid cells and plasma cells in 
varying stages of maturation. The supporting framework is formed by the 
capsule, trabeculae, reticulinfibres and network of vesicular cells. The 
fibroblasts along with smooth muscle cells, nerve bundles, Schwann cells 
and blood vessels constitute capsule which extends into the underlying 
parenchyma as trabeculae.   
           The reticulinfibres which originate from reticulin cells are fine type 3 
collagen fibrils, which form the main supporting framework of the lymph 
node. Reticulinfibres surround individual lymphoid cells, hence are not 
visualised under H&E stain. It can be well demonstrated by using silver 
impregnation technique (Gomori‘s technique). 
CORTEX 
          The cortical region of lymph node is primarily composed of lymphoid 
follicles. Lymphoid follicles can either be primary or secondary. Primary 
follicles are usually round to ovoid nodular collection of dark staining naive 
B cells. They are arranged with their long axis perpendicular to the lymph 
node 
(5)
.They transform into secondary follicles after antigenic stimulation.  
           The secondary follicles, that are transformed primary follicles, are 
composed of central pale staining germinal centre, a mantle zone and a 
marginal zone. Germinal centres are formed by the mixture of centroblasts, 
centrocytes, dendritic reticulum cells, small lymphocytes which are 
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primarily B-cells and tingible body macrophages with few scattered T 
lymphocytes. The germinal centres are cuffed off by small lymphocytes 
which form the mantle zone. The peripheral portion of the mantle zone is 
composed of cells that are loosely packed forming the marginal zone. The 
marginal zones are distinctly made out in the reactive follicles of spleen and 
usually are not so evident in the lymph nodes.  
PARACORTEX 
Paracortical areas are the T-cell packed zones in the lymph nodes and 
they are located deep beneath the cortex extending in between the lymphoid 
follicles. These areas are composed of T-cells in various stages of 
maturation 
(6)
, admixed with post capillary venules lined by high endothelial 
cells. In addition, there are interdigitating dendritic cells which serve as 
antigen presenting cells. They play an important role in evoking an immune 
response.  
MEDULLARY AREA 
          This is located deep to the cortex and is primarily composed of 
plasmacytoid lymphocytes, plasmablasts, mature plasma cells and cords of 
lymphocytes. The plasma cells lose their surface markers and synthesize 
immunoglobulins of varying classes with kappa and lambda chain in the 
ratio of 2:1
(7)
. In addition to plasma cells, the medullary area also contains 
monocytes and macrophages.  
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CELLULAR COMPOSITION 
          The lymph node is formed by B-cell zone and T-cell zone containing 
cells in various stages of activation and differentiation. Germinal centres 
and lymphoid follicles are the B-cell zone whereas the paracortical area 
forms the T-cell zone. The medullary region is predominantly formed by the 
plasma cells. 
          The dark staining naive B cells that forms the primary follicles also 
accounts for the mantle zone of the secondary follicles 
(8)
. These are small 
cells with scant cytoplasm and increased nuclear cytoplasmic ratio. 
Centroblasts are large cells that form the dark zone in the germinal centres 
which express IgM on their surface. They differentiate into centrocytes 
which forms the light zone in the germinal centres.  
              Some of the centroblasts that differentiate into memory cells reside 
in the mantle zone whereas those that are transformed into plasma cells 
move into the medullary region. The histiocytes are the transformed 
monocytes in the tissues that accumulate in the paracortical areas and 
germinal centres secondary to immune activation. These are large cells that 
contain abundant neither strongly basophilic nor pyroninophilic cytoplasm. 
These can be differentiated from large lymphocytes with the help of 
ultrastructural and immunohistochemical study. The histiocytes that 
accumulate in the germinal centres form the tingible body macrophages. 
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The tingible body macrophages contain numerous DNA fragments formed 
secondary to cell death after bcl-2 gene gets shut off. 
NORMAL LYMPH NODE AND IHC 
              The main application of immunohistochemistry in normal lymph 
node is to study the differential expression of the same antibody in various 
regions of the lymph node and assess the cellular composition and clone of 
the lymphoid cells. Studying the clone among various lymphoid populations 
helps us to differentiate reactive hyperplasia from neoplastic transformation 
of the lymph node, more importantly Non Hodgkin lymphoma.  
         B cells in the lymphoid follicles usually express pan-B cell marker 
such as CD19, 20, 22 and 79a. In addition, centroblasts express CD10 and 
cells of the germinal centre show positive expression of Bcl-6 in the 
nucleus. Bcl-2 which is an anti-apoptotic protein is usually shut off in the 
germinal centre and shows positive expression in the mantle & marginal 
zone. Naive B cells in the primary follicle and mantle zone expresses CD5 
with surface IgM and IgD. [IgD is not expressed in the germinal centre]. 
        The B-centroblast expresses IgM on their surface which shifts to 
IgD/IgA in the case of centrocytes. Immunoglobulin Kappa and lambda 
expression is usually seen in all the B lymphocytes but monoclonality points 
towards neoplastic transformation. In addition, positive expression of Bcl-2 
in germinal centre is a feature of neoplastic transformation. 
(9,10,11)
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               The small lymphocytes that are scattered throughout the germinal 
centre show positive expression for CD3, CD5, CD7, CD43 and CD4/8 that 
gives a clue that they are reactive T cells. Tingible body macrophages stain 
with CD11b, CD35 and CD68 whereas dendritic reticulum cells stain with 
CD21, 35, C3b, C3d. 
(12)
 
           The cells in the paracortical region stain  with pan T cell markers like 
CD2, CD3, CD5 and CD7, CD43 and HLA-DR. Interdigitating dendritic 
cells show positive expression for S100, CD24, HLA- DR. Plasma cells are 
CD138(Syndecan 1) positive. Macrophages stain for lyzozyme, α1-
antitrypsin, S100 protein and CD68. 
(13,14) 
LYMPHOMA 
           Lymphomas and leukemias are the two challenging fields in medical 
investigation in which immunity and neoplasia interface. It is very important 
to identify the cases of lymphoma and differentiate it from various types of 
non neoplastic lymphadenopathies.  Once the presence of lymphoma has 
been identified, it should be classified into Hodgkin and Non Hodgkin 
lymphoma.  The Non Hodgkin lymphoma should be further subclassified 
morphologically, immunologically and phenotypically so as to establish the 
exact diagnosis for the purpose of therapy and prognosis. There are many 
modes of investigations to diagnose malignant lymphomas which include 
cytomorphology, radiology, immunology and molecular techniques. Hence, 
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proper selection of the investigations will facilitate correct diagnosis at a 
reasonable expense to the patient.  
NON HODGKIN LYMPHOMA 
Non Hodgkin lymphomas are clonal lymphoproliferative disorders 
characterised by proliferation of malignant lymphoid cells that forms 
discrete mass. This includes diverse group of tumor of B-cells, T-cells and 
natural killer cell origin. Majority of the cases of non Hodgkin lymphomas 
are of B-cell origin while the remainder of the cases has T-cell origin. Non-
Hodgkin lymphoma very rarely involves natural killer cells. Most of the 
lymphoid neoplasms resemble some recognizable stage of B-cell or T-cell 
differentiation with neoplastic lymphoid cells recapitulating the behaviour 
of their normal counterpart. 
In earlier days it was believed that lymphadenopathy was a secondary 
phenomenon occurring secondary to underlying infection or carcinoma. 
Thomas Hodgkin first recognised that lymph node enlargement could occur 
as a primary disorder rather than secondary to underlying infection or 
carcinomas
(15)
. Billroth was the first one who used the term malignant 
lymphoma for a collection of primary lymphoid disorders
(16)
. 
During eighteenth century Sternberg
(17)
 and Reed
(18)
first identified the 
giant cells which are considered as the characteristic feature of Hodgkin 
lymphoma and introduced histopathological examination as the primary 
method of diagnosis and classification of lymphoproliferative disorders. 
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Brill
(19)
and Symmers
(20)
, in 1920, described the features of follicular 
lymphoma. In 1956, Rappaport through his classical work classified Non-
Hodgkin lymphoma based upon the morphology of the malignant lymphoid 
cells 
(21)
. Roulet
(22)
 in 1930 considered reticulum cell sarcomas as a synonym 
for malignant lymphomas. 
In 1967, Good and Finstad demonstrated the relationship of B 
lymphocytes and T lymphocytes to the development of lymphoid 
neoplasms. Later Dameshek, through his work, suggested that 
lymphoproliferative disorders primarily occurs due to aberrations of 
immunologically competent cells and also lymphoid cells has the potential 
to get transformed into immunoblast like cells under appropriate antigenic 
stimulation. Immunological origin of malignant lymphocytes was confirmed 
in 1972 by the presence of immunoglobulins over the surface of B 
lymphocytes and by the formation of sheep erythrocyte rosette with 
neoplastic T lymphocytes 
(23, 24)
. 
Lennert, Lukes and Collins at United States in 1974, classified Non-
Hodgkin lymphoma based on cell of origin into B cell and T cell 
lymphomas 
(25, 26)
.Later in 1980, origin of lymphoid neoplasm was 
confirmed at molecular level after a detailed study on immunoglobulin gene 
over B lymphocytes and T cell receptors over T lymphocytes 
(27, 28)
. 
Working formulation in 1982 classified Non-Hodgkin lymphoma based 
upon the histological grade and correlated it with the patient survival. From 
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1994, Revised European American Lymphoma classification came into use, 
which classified lymphoma based upon the clinical features, morphology, 
immunophenotyping and genetic data which were available
(29)
. Finally 
World Health Organisation has adopted the diagnostic principle of REAL 
classification and now WHO classification is used as schema for the 
diagnosis of all hematopoietic neoplasm. 
Non Hodgkin Lymphoma and non modifiable risk factors   
Non-Hodgkin lymphomas are the sixth most common cancer 
worldwide. Frequency of Non-Hodgkin lymphoma is age dependent and has 
variable distribution worldwide. Non-Hodgkin lymphomas are more 
common in males than females and hence show male preponderance. 
Malignant lymphomas are most common among adults and accounts for 
only 10% of all childhood malignancies in developed countries. Non-
Hodgkin lymphomas show a steady increase in incidence from childhood 
through age of 80 years
(30)
. 
Increased risk for development of Non Hodgkin lymphoma has been 
documented among close relatives. There is two to four fold increased 
incidence of Non-Hodgkin lymphoma among close relatives of patients with 
lymphoma
(31)
. Aggregations have been reported among siblings and male 
relatives 
(32, 33)
. Earlier age of onset in subsequent generation has been 
recorded in Non-Hodgkin lymphoma
(34)
. Increase in incidence of 
lymphoproliferative disorders is seen in association with autoimmune 
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lymphoproliferative syndrome which includes autoimmune features, 
splenomegaly and chronic lymphadenopathy
(35)
. Malignant lymphomas are 
more common among people with family history of lymphoma
(36)
. 
Young age and Non Hodgkin Lymphoma                     
Malignant lymphomas are the third most common cause of childhood 
neoplasms next to brain tumours and acute lymphoblastic leukaemias
(37,38)
. 
There is increased risk for Hodgkin lymphoma among the children less than 
18 years, whereas Non Hodgkin lymphomas accounts for majority of the 
cases below 15 years. There occur many differences in the manifestations of 
Non-Hodgkin lymphomas of adults and children. Lymphomas among the 
children are high grade with frequent extranodal manifestations, which in 
adults are primarily nodal and usually of low grade and intermediate grade. 
Non-Hodgkin lymphomas in children are more common in boys when 
compared to girls and occur more frequently in blacks than whites. The 
three most important Non Hodgkin lymphomas occurring among children 
are Burkitt‘s lymphoma, lymphoblastic lymphomas and large cell 
lymphomas
(39)
. Large cell lymphomas are characterised by neoplastic 
transformation of lymphoid cells which are larger than the diameter of the 
histiocytic nucleus. This includes diffuse large B-cell lymphomas, 
anaplastic large cell lymphomas and peripheral T-cell lymphomas among 
which anaplastic large cell lymphomas are most common followed by 
diffuse large B-cell lymphomas. But overall, lymphoblastic lymphomas 
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forms bulk of the pediatric lymph node malignancies. Follicular lymphomas 
and marginal zone lymphomas occurs rarely and are considered uncommon 
neoplasms in the childhood.   
 
  Infection and Non Hodgkin Lymphoma 
                   Infections play a major role in lymphomagenesis. The 
development of lymphoma depends on various factors including 
environment, geography and host factors 
(40)
. Infectious agents cause 
lymphoma through direct lymphocyte transformation. Most of the infectious 
agents that cause lymphomas are found to be viruses which include EBV, 
HTLV-1, HHV8. Chronic infection by hepatitis-C virus can result in B-cell 
Non-Hodgkin lymphoma
(41)
. Indolent B cell lymphoma, lymphoplasmacytic 
lymphoma and marginal zone lymphoma are the most common types of 
lymphomas that are associated with hepatitis-C virus.  
Ebstein-Barr Virus plays an important role in the causation of Non 
Hodgkin lymphoma. It has worldwide distribution accounting for more than 
80% of the people over 30years of age. Once EBV infection has occurred it 
remains for life time of the individual. It usually affects children, but also 
can involve adolescence and adulthood. EBV usually establishes 
asymptomatic persistent infection, but due to effective immune mechanism 
only few of the infected carriers develop spontaneous EBV-associated Non-
Hodgkin lymphoma. EBV has unique genes that cause growth activation of 
infected B-cell. The lymphomas caused by Ebstein-Barr Virus include T-
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cell lymphoma, post transplant Non-Hodgkin lymphoma, AIDS related 
Non-Hodgkin lymphoma, Burkitts lymphoma and Hodgkin lymphoma. 
Human T-cell lymphotrophic virus are the first retrovirus discovered, 
the infection of which is strongly associated with adult T-cell 
leukemia/lymphoma. It is endemic in south Japan, Caribbean, South Africa 
and South America. Human T-cell lymphotrophic virus 1 infection increases 
with age and is twice as high in females when compared to males. The 
infection is usually asymptomatic to start with but manifests typically later 
in the life. The incidence of infection is found to be increased in breast fed 
infants than in bottle fed infants. 
Hepatitis–C Virus is found to be related to lymphomagenesis. 
Infections usually occur through blood transfusion and needle stick injuries. 
It is believed that HCV causes lymphoma by chronic antigenic stimulation. 
Infection of Hepatits C virus is associated with increased risk of Diffuse 
large B-cell lymphoma, Marginal zone lymphoma and lymphoplasmacytic 
lymphoma. Human herpes virus-8 has been documented in the causation of 
Non-Hodgkin lymphoma. HHV infection is associated significantly and 
positively with risk of lymphoplasmacytic lymphoma. 
Genetic polymorphism associated with the risk of Non Hodgkin 
lymphoma suggests that single nucleotide polymorphism in Tumor necrosis 
factor and Interleukin-10 are associated with increased risk of Non-Hodgkin 
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lymphoma especially  Diffuse large B-cell lymphoma. Alcohol consumption 
appears to be inversely related to Non-Hodgkin lymphoma. Smoking does 
not appear to play a role in etiology of Non-Hodgkin lymphoma.    
Helicobacter pylori is a gram negative rod that was discovered by 
Warren and Marshall in 1983 and was shown to be associated with peptic 
ulcer disease, carcinoma of stomach and Non Hodgkin lymphoma 
(42, 43)
. 
Later on Personett recognised that Helicobacter pylori infection preceded 
the development of lymphoma
(44)
 and Wotherspoon observed that there is 
regression of lymphoma in most of the patients after treatment with 
antibiotics
(45)
. Other infectious agents includes, campylobacter jejuni which 
causes small intestinal immunoproliferative diseases, Borrelia burgdoferi 
which causes primary cutaneous B cell lymphoma and Chlamydia psittaci 
which is the causative agent for ocular adnexal MALTomas
40
. 
AIDS and transplant related Non Hodgkin Lymphoma 
Lymphomas both Hodgkin and Non Hodgkin can be secondary to 
infection by Human immunodeficiency virus. Non-Hodgkin lymphomas can 
occur in setting of underlying congenital and acquired 
immunodeficiencies
(46)
. After Kaposi sarcoma, lymphomas are the most 
common AIDS related cancer 
(47)
. NHL occurs in 3% of the patients 
suffering from AIDS 
(48)
, with sixty time greater risk of acquiring 
lymphomas when compared to persons without infection. Most of the Non-
18 
 
Hodgkin lymphoma represents B-cell type, among which 70% is constituted 
by diffuse large B-cell lymphomas and the remaining being Burkitt‘s 
lymphoma. Among patients of lymphomas found in the general population 
of young patients in which Hodgkin lymphomas are more common, 
lymphomas in AIDS patients are mostly Non Hodgkin type with frequent 
extranodal manifestations 
(49, 50)
. The occurrence of lymphomas in AIDS can 
be attributed to florid activation of lymphoid cells which provides 
opportunity for translocation, mutation and deletion of tumor suppressor 
gene 
(51, 52)
. 
Post-transplant lymphoproliferative disorders include both 
polymorphic and monomorphic proliferation of lymphoid cells. PTLPD are 
most common during first year after solid organ and bone marrow 
transplant. The persons with multiple organ transplants are at increased risk 
of developing post transplant lymphoproliferative disorders. Lymphoid cell 
proliferation can occur in patients both with and without EBV infection. The 
main cause for occurrence of both polymorphic and monomorphic 
proliferation can be attributed to mutation in the variable region of 
immunoglobulin 
(53)
. These mutations have been found in about 75% of 
polymorphic PTLPD and 90% of monomorphic proliferation. Among 
monomorphic proliferation Burkitt‘s lymphomas constitute the bulk of the 
lymphomas, remaining being cases of Diffuse large B-cell lymphomas.    
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Autoimmune and other disorders 
Chronic inflammation, immune hyperactivity and 
immunosuppression are considered to be important elements that predispose 
patients to lymphoma 
(54)
. Non-Hodgkin lymphomas associated with 
Sjogren‘s syndrome and Hashimoto‘s thyroiditis are of B-cell origin and 
they usually occur in elderly females. In 1963, Bunin and Talal
(55)
 reported 
Non-Hodgkin lymphoma in a case of Sjogren‘s syndrome. In 1957, Lindsay 
and Dailey 
(56) demonstrated the association of lymphoma with Hashimoto‘s 
thyroiditis. There is 60 to 80 fold increase in thyroid lymphomas among the 
cases of thyroiditis with lifetime risk of 1-2% 
(57)
.  Non-Hodgkin lymphoma 
has been associated with rheumatoid arthritis, SLE, and dermatomyositis.  
Non-Hodgkin lymphoma has been observed to originate from treated 
cases of Hodgkin lymphoma. Krikorian 
(58)
reported 6 cases of Non-Hodgkin 
lymphoma arising from Hodgkin lymphoma. First case of Non-Hodgkin 
lymphoma associated with AIDS has been reported in 1982 
(59)
. Majority of 
the lymphomas arising from AIDS patients are of B-cell origin. Unique 
presentation of AIDS related lymphomas include plasmablastic lymphomas 
of oral cavity 
(60) 
and primary effusion lymphomas 
(61)
. 
Non Hodgkin Lymphoma and presentation 
Most of the cases of Non-Hodgkin lymphoma presents as painless 
lymphadenopathy in cervical and supraclavicular region 
(62)
. However, 40% 
of patients have extranodal presentation. Gastro intestinal tract is the most 
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common extra nodal site of presentation, in which stomach is the 
commonest site followed by small intestine, colon and esophagus, in that 
order. Rarely, patients with rectal involvement present with altered bowel 
habits 
(63)
. Epistaxis and nasal obstruction are the modes of presentation in 
cases of Non-Hodgkin lymphoma of nasal cavity. Hepatosplenomegaly have 
been observed in cases of low grade B-cell lymphomas such as small B-
lymphocytic lymphomas and marginal zone lymphomas. Skin is another 
most common site of Non-Hodgkin lymphoma presentation. Non-Hodgkin 
lymphoma can primarily involve CNS 
(64)
 in which diffuse large B-cell 
lymphomas are the most common. Other rare sites involved are eye, 
extraocular space including conjunctiva, eyelids & lacrimal glands 
(65)
, 
testis, kidney and breast. Breast lymphomas associated with pregnancies and 
lactation often has diffuse involvement 
(66)
. Primary cardiac lymphomas are 
extremely rare and usually occur in immunodeficient state 
(67)
. 
Gray zone lymphomas 
Malignant lymphomas are classified into Hodgkin and NHL based on 
morphological pattern, cell type and more importantly based on the analysis 
of antigenic expression. Both should be differentiated as they require 
distinct treatment for regression. The new modes of investigations like 
immunophenotyping and genetic analysis have revealed that there exist 
certain lymphoid neoplasms that can neither be classified as Hodgkin 
lymphoma nor as NHL. These were given the name, gray zone lymphomas 
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(68, 69)
. This includes nodular lymphocyte predominant Hodgkin lymphoma, 
T cell rich large B cell lymphoma, Anaplastic large cell lymphoma, 
peripheral T-cell lymphoma and primary mediastinal large B-cell 
lymphoma. 
Gray zone lymphomas should be separated from conventional 
lymphomas as they are aggressive and require distinct treatment 
(70, 71)
. 
CLASSIFICATION OF NON-HODGKIN LYMPHOMA 
           Currently, lymphoma diagnosis is based upon the classification of 
World Health Organisation, which relies upon the morphology of the node 
including pattern, cell size and shape, radiological features, flow cytometry 
and IHC for evaluating the antigenic expression and finally cytogenetics. 
Based upon these, lymphoma has been classified by WHO into Hodgkin and 
Non Hodgkin lymphoma. The Hodgkin Lymphoma has been broadly 
classified into nodular lymphocytic predominant HL and classic Hodgkin 
lymphoma. The Non Hodgkin lymphoma has been further classified into B 
and T cell lymphomas which are sub-classified as precursor and peripheral 
(mature) B cell and T cell Non Hodgkin lymphoma, respectively.  The 
precursor B and T cell lymphomas represent the neoplastic transformation 
of the progenitor cells which are not exposed to antigens, hence are in an 
inactivated and undifferentiated stage. The peripheral lymphomas arise from 
the rest of the lymphoid cells in various stages of maturation. 
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              Mature B cell neoplasm constitutes about 90% of NHL 
worldwide
(72)
. B cell represents all follicular and diffuse lymphomas in 
North America and Europe, whereas T cell lymphomas are most common in 
Asia 
(73)
. The nomenclature, classification and differentiation of various 
types of lymphomas depend upon various factors including the cell of origin 
eg; mantle cell lymphomas, clinicopathological name eg: Burkitt‘s 
lymphoma, their location eg: mediastinal large B cell lymphomas and 
presumed fuction eg; MALTomas. 
             The grade and prognosis of Non Hodgkin lymphomas depend upon 
the morphological pattern, size and shape of the cell, mitosis and 
invasiveness. The pattern of neoplastic transformation is divided into 
nodular and diffuse in which the nodular growth pattern represents the 
differentiation of malignant lymphomas towards lymphoid follicles. The 
malignant lymphoma cells are classified into small, medium and large sized 
by comparing the nucleus of the neoplastic cells to the adjacent histiocytes 
or endothelial cells. On the basis of shape, it is classified into cleaved and 
non-cleaved in which the cleaved cells represent non-dividing cells and non-
cleaved represent the dividing cells. In general, lymphomas are considered 
aggressive when the cells are large, non-cleaved with a diffuse pattern of 
growth showing increased mitosis and invasion.  
              T cell neoplasms are less common when compared to B cell 
lymphomas in western countries, representing 20% of the Non Hodgkin 
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lymphoma 
(74)
. T cell lymphoma along with NK cell lymphomas account for 
12% of all the NHLs 
(75)
. They are classified similar to B cell neoplasms into 
precursor (or) thymic T cell lymphoma and mature (or) peripheral T cell 
lymphomas. The largest group which represents peripheral T cell 
lymphomas is the T cell lymphoma NOS type, accounting for more than 
50% of the cases of T cell lymphomas. Generally, the T cell lymphomas are 
aggressive with a 5 year survival rate of only 20-30% which are 
characterised by diffuse growth pattern, with mixed population of small and 
large cells in an inflammatory background. More frequently, epitheloid cells 
and eosinophils are also made out. 
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MODIFIED KIEL CLASSIFICATION 
(76) 
KIEL CLASSIFICATION  Nearest 
correspondence to 
categories of 
Rappaport  
classification  
Nearest 
correspondence to 
categories of Lukes-
Collins classification  
LYMPHOMAS OF LOW 
GRADE MALIGNANCY  
  
Lymphocytic lymphomas    
1. Chronic lymphocytic  
leukemia (B-cell type)  
Well-differentiated 
lymphocytic 
lymphoma  
B cell lymphoma of 
small lymphocytes  
2.Hairy cell leukemia                          -                  -  
3.Mycosis fungoides and 
Sezary‘s syndrome  
                        -  T-cell 
lymphomas:.Mycosis
fungoides and 
Sezary‘s syndrome  
4.Chronic lymphocytic 
leukemia (T- cell type)  
                        -               -  
Lymphomas of immunoglobulin 
-secreting cells  
Apart from 
lymphomas-
‘proliferative diseases 
with dysprotinemia‘  
 
1.Lymphoplasmacytic/lympho
plasmacytoid lymphoma  
                   -  B-cell lymphoma of 
plasmacytoid 
lymphocytes  
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2.Plasmacytic lymphoma                     -                  -  
Lymphomas of germinal centre 
cells  
  
1.Centrocytic lymphoma  well –differentiated 
& poorly 
differentiated 
lymphocytic 
lymphomas; Mixed 
cell(lymphocytic- 
Histiocytic) 
lymphoma;Histiocyti
c lymphoma 
B-cell lymphoma of 
follicular centre cells 
with cloven nucleus 
(diffuse type)  
2.Centroblastic /centrocytic 
lymphoma 
    follicular 
    follicular and diffuse 
    diffuse 
    with or without sclerosis  
well –differentiated 
& poorly 
differentiated 
lymphocytic 
lymphomas; Mixed 
cell(lymphocytic- 
Histiocytic) 
lymphoma; 
B-cell lymphoma of 
follicular centre cells 
with cloven nucleus  
LYMPHOMAS OF HIGH 
GRADE MALIGNANCY 
  
Centroblastic lymphomas  Histiocytic 
lymphoma; 
undifferentiated 
lymphoma  
B-cell lymphoma of  
large follicular centre 
cells with  non-cloven 
nucleus  
1.Primary    
2.Secondary    
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Lymphoblastic lymphomas 
(lymphoblastic sarcomas, 
including acute lymphoblastic 
leukemia)  
Undifferentiated 
lymphoma; poorly 
differentiated 
lymphocytic 
lymphoma  
B-cell lymphoma of  
small follicular centre 
cells with  non-cloven 
nucleus  
1.Burkitt lymphoma  Undifferentiated 
lymphoma  
As above  
2.Lymphoma of convoluted 
cells [i.e., cells with 
convoluted nucleus]  
Undifferentiated 
lymphoma; poorly 
differentiated 
lymphocytic 
lymphoma  
T-cell lymphoma of 
convoluted 
lymphocytes  
3.Unclassified lymphoma  poorly differentiated 
lymphocytic 
lymphoma  
U-cell (‗undefined 
cell‘) lymphoma; 
unclassifiable 
lymphomas.  
Immunoblastic lymphomas  Histiocytic lymphoma  Immunoblastic 
sarcoma of B cells; 
immunoblastic 
sarcoma of T cells  
With plasmablastic/ 
plasmacytic differentiation 
(derived from B cells)  
  
Without 
plasmablastic/plasmacytic 
differentiation (derived from B 
cell or T cell)  
  
(a) Leukemic variant 
(immunoblastic leukemia)  
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[This table represents Kiel classification modified by Lennert et al in 
1977
(76)
. The Kiel classification and Lukes-Collins classification relates to 
the functional characteristics of the cells that relate to the tumors.] 
 
A WORKING FORMULATION OF NON-HODGKIN 
LYMPHOMAS
(77) 
 This classification was introduced in 1982 by National cancer 
institute, United States 
(77)
, as an attempt to provide a morphologic 
classification scheme that had a prognostic relevance. 
LOW- GRADE 
Malignant lymphoma 
      Small lymphocytic 
          Consistent with chronic lymphocytic leukemia 
          Plasmacytoid 
Malignant lymphoma, follicular 
      Predominantly small cleaved 
          Diffuse areas;sclerosis 
Malignant lymphoma, follicular 
      Mixed, small cleaved and large cells  
  Diffuse areas;Sclerosis 
INTERMEDIATE-GRADE 
Malignant lymphoma, Follicular 
      Predominantly large cell  
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          Diffuse areas; Sclerosis 
Malignant lymphoma, Diffuse  
     Small cleaved 
          Sclerosis 
Malignant lymphoma, Diffuse 
     Mixed, small and large cell  
          Sclerosis; Epithelioid cell component 
Malignant lymphoma, Diffuse 
     Large cell 
 Cleaved, non cleaved; Sclerosis 
HIGH GRADE 
Malignant lymphoma 
     Large-cell, Immunoblastic 
Plasmacytoid; clear cell; polymorphic; epithelioid cell component 
Malignant lymphoma 
      Lymphoblastic 
           Convoluted; non convoluted 
Malignant lymphomas 
      Small noncleaved 
           Burkitt; Follicular areas 
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MISCELLANEOUS 
Composite 
Mycosis fungoides 
Histiocytic 
Extramedullaryplasmacytoma 
Unclassifiable 
Others 
 
WORLD HEALTH ORGANISATION CLASSIFICATION OF 
LYMPHOID NEOPLASMS (INTERNATIONAL AGENCY FOR 
RESEARCH ON CANCER, LYON, 2008) 
(78) 
This classification is based on the collaborative project of European 
Association for Haematopathology and society for Hematology.  This 
classification is based on principles initially defined in the ―Revised 
European-American Classification of Lymphoid Neoplasms‖ (REAL), from 
the International Lymphoma Study Group (ILSG) 
(29)
. 
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PRECURSOR B- AND T-CELL NEOPLASMS 
Precursor B-lymphoblastic leukaemia/lymphoblastic lymphoma 
Precursor T-lymphoblastic leukaemia/lymphoblastic lymphoma 
 
MATURE B-CELL NEOPLASM 
Chronic lymphocytic leukaemia/ Small lymphocytic lymphoma 
B-cell prolymphocytic leukaemia 
Lymphoplasmacytic lymphoma 
Splenic b-cell marginal zone lymphoma 
Hairy cell leukaemia 
Plasma cell myeloma 
Solitary plasmacytoma of bone 
Extraosseous plasmacytoma 
Heavy chain disease 
MALT-lymphoma 
Nodal marginal zone B-cell lymphoma 
Follicular lymphoma 
Mantle cell lymphoma 
Diffuse large B-cell lymphoma, NOS 
DLBCL associated with chronic inflammation 
Lymphomatoid granulomatosis 
31 
 
Mediastinal large B-cell lymphoma 
Intravascular large B-cell lymphoma  
ALK positive large B-cell lymphoma 
Plasmablastic lymphoma 
Primary effusion lymphoma 
Burkitt lymphoma 
B-cell lymphoma, unclassifiable with features intermediate between 
DLBCL &Burkitt lymphoma 
B-cell lymphoma, unclassifiable with features intermediate between 
DLBCL and classic Hodgkin lymphoma 
 
MATURE T-CELL AND NK-CELL NEOPLASM 
T-cell prolymphocytic leukaemia 
T-cell large granular lymphocytic leukaemia 
Aggressive NK-cell leukaemia 
Adult T-cell leukaemia/lymphoma 
Systemic EBV positive T-cell lymphoproliferative disease of childhood 
Hydroa vacciniforme-like lymphoma 
Mycosis fungoides 
Sezary syndrome 
Primary cutaneous anaplastic large cell lymphoma 
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Primary cutaneous CD30 positive T-cell lymphoproliferative disorder 
Primary cutaneous gamma-delta T-cell lymphoma 
Lymphomatoid papulosis 
Extranodal NK/T-cell lymphoma, nasal type 
Enteropathy-type T-cell lymphoma 
Hepatosplenic T-cell lymphoma 
Subcutaneous panniculitis- like T-cell lymphoma 
Angioimmunoblastic T-cell lymphoma 
Peripheral T-cell lymphoma 
Anaplastic large cell lymphoma 
 
HODGKIN LYMPHOMA 
Nodular lymphocyte predominant Hodgkin lymphoma 
Classical Hodgkin type 
         Nodular sclerosis classical Hodgkin lymphoma 
         Mixed cellularity classical Hodgkin lymphoma 
         Lymphocyte rich classical Hodgkin lymphoma 
         Lymphocyte depleted classical Hodgkin lymphoma 
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CELLS OF ORIGIN OF NON HODGKIN LYMPHOMA 
 
 Figure 1
(79)
: Origin of lymphoid neoplasms. Stages of B- and T-cell 
differentiation from which specific lymphoid tumors emerge are seen. 
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As seen in the above illustration, the immature B- cells and T-cells derived 
from the bone marrow are the cells of origin for precursor B-cell and T-cell 
lymphomas/leukemias, respectively. The germinal centre B cell gives rise to 
burkitt lymphoma, follicular lymphoma and diffuse large B-cell lymphoma. 
DLBCL also arises from the post germinal centre B-cells. The post germinal 
centre memory B-cells give rise to hairy cell leukemia, extranodal marginal 
zone lymphoma and CLL/SLL. The peripheral T cell lymphomas of nodal 
origin arise from the T cells in the paracortical area of the lymph node. 
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Figure 2
(80)
: cellular origin of Non Hodgkin Lymphoma based on B cell and 
T cell differentiation 
 
 
 
 
36 
 
 The above illustration shows the different classes of lymphoma based 
on Lukes-Collin classification. The B cell lymphoma of small lymphocytes 
constitutes CLL/SLL, whereas the B-cell lymphoma of follicular centre 
cells with cloven nucleus (diffuse type) constitutes the centrocytic 
lymphoma. B-cell lymphoma of large follicular centre cells with non-cloven 
nucleus constitutes centroblastic lymphoma , whereas B-cell lymphoma of 
small follicular centre cells with non-cloven nucleus constitute 
lymphoblastic lymphoma. 
IMMUNOHISTOCHEMISTRY 
Immunohistochemistry is a technique which is used to detect the 
specific antigens over the tissues or cells based on the pattern of antigen-
antibody reaction. Coons 
(81)
 in 1940 introduced immunoflorescence to 
localise corresponding antigen in frozen section. The enzymatic label 
horseradish peroxidase developed by Avrameas
(82)
 and by Nakane and 
colleagues
(83)
 provided the new path for the visualisation of the labelled 
antibody by light microscopy in the presence of a appropriate colorigenic 
substrate system. 
The aims of immunohistochemistry are akin to those of 
histochemistry. Indeed, immunohistochemistry builds on the foundations of 
histochemistry. Immunohistochemistry does not replace histochemistry but 
rather serves as the valuable adjunct that greatly extends the variety of tissue 
components that can be demonstrated specifically with tissue sections. The 
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main aim of performing IHC is to recognize microchemically the existence 
and distribution of substances which we have been made aware of 
macrochemically
(84)
. Immunohistochemistry can provide a tissue based 
immunoassay with the reproducibility and quantitative characteristics of an 
ELISA test.   
Demonstration of antigen in routinely processed formalin-fixed 
paraffin embedded tissues
(85)
 was done for the first time in 1974 by Taylor 
and Burns in Oxford.Then as the immunohistochemistry evolved, its 
utilisation in diagnostic pathology steadily expanded such that more than 
one immunohistochemistry markers were used in routine surgical pathology 
especially with respect to tumour diagnosis and classification. The 
introduction of hybridoma technique
(86)
 facilitated in the development of 
immunohistochemistry and the manufacture of many highly specific 
monoclonal antibodies. 
The phenomenon of enzyme digestion was then introduced by Huang 
as the pretreatment to immunohistochemistry staining to unmask some 
antigens that had been altered by formalin fixation 
(87)
. The main 
disadvantage of using enzyme digestion was that it proved difficult to 
control the optimal digestion conditions for different tissue sections when 
stained with different antibodies. Hence, to overcome the difficulties 
encountered in enzyme digestion Shi and his associates in 1991
(88, 89, 90, 91, 92, 
93)
 introduced antigen retrieval technique, based on series of studies by 
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Fraenkel and co-workers 
(94, 95, 96)
. Various modifications of antigen retrieval 
has been described, among which majority of those used different buffer 
solution in the place of metal salt solution, which may have serious toxic 
effect
(97, 98)
.    
Antigen and antibody reaction                               
An antibody is a molecule that has the property of combining 
specifically with the antigen. Antigen-antibody recognition is based on three 
dimensional structure of the protein. Antibodies are immunoglobulin 
molecules containing pair of light chain and pair of heavy chain. An epitope 
is an antigenic determinant on which the antibody combines. For a protein, 
the term epitope corresponds to a cluster of aminoacid residues that binds 
specifically to the paratope of an antibody 
(99)
.  
Antigen-antibody reaction depends on two factors that are related to 
antibody which includes sensitivity and specificity. Antibodies are primarily 
of two types monoclonal and polyclonal. Comparitive studies on sensitivity 
and specificity among monoclonal and polyclonal antibodies proves that 
polyclonal antibodies are more sensitive and less specific than monoclonal 
antibodies. The reason may be polyclonal antibody which is a composite of   
many antibodies may recognise several binding epitope whereas 
monoclonal antibody recognise single type of epitope. 
Most of the monoclonal antibodies in current use are derived from 
murine clones. Recently a number of rabbit derived monoclonal antibodies 
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have appeared on the market. Some of the rabbit derived antibodies offer 
advantage over murine clones for the detection of antigens by 
immunohistochemistry.   
Enzyme labels in immunohistochemistry                                    
Enzymes are the widely used labels used in immunohistochemistry.  
Incubation with the chromogen using proper histochemical method 
produces stable colour reaction end product that can be easily read by using 
light microscopy. Variety of enzymes and chromogens are available which 
produces many number of coloured end products. Horseradish peroxidase is 
the most commonly used enzyme label. When used in conjunction with 
most favoured chromogen like Diaminobenzidine tetrachloride yield 
insoluble, stable brown coloured end product. Horseradish peroxidase is 
most preferred as they are very small in size, and can be very easily 
obtained in pure form. It is very stable and does not undergo alteration 
during manufacture, storage and during application. 
Various other chromogens are also used based on the choice of end 
product coloured reaction. Graham in 1965 used 3-amino 9-ethyl carbazole 
which produces red colour. Later in 1968, Nakane used 4-chloro 1-napthol 
produces blue colour. Hanker in 1977, used Hanker- Yates reagent, that 
produces a dark blue colour. Commercially chromogens are available in Kit 
form such as vector laboratories which used vector red and vector blue. 
Alternatives to Diaminobenzidine tetrachloride are more commonly used in 
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multilabelling technique. Rarely colloid metal label such as gold conjugates 
are used. When used alone it appears pink under microscope. A silver 
precipitation reaction can be used to amplify the visibility of gold 
conjugates. The use of radioisotopes as the tracer requires autoradiographic 
facilities.          
Antigen retrieval 
Antigen retrieval is the process of reversal of chemical reaction that 
has occurred between formalin and protein. Heat induced antigen retrieval 
technique is now widely used in pathology
(100)
. It has certainly brought a 
very good improvement in the quality of immunohistochemistry. The 
optimal result of antigen retrieval in immunohistochemistry depends on 
heating temperature, period of heating and PH of antigen retrieval solution.  
            Various methods are used in the process of antigen retrieval which 
includes microwave antigen retrieval, pressure cooker antigen retrieval and 
retrieval using streamer, water-bath, autoclave and combined microwave 
and trypsin digestion antigen retrieval. The use of conventional heating at 
100
0
c achieves results similar to those obtained by microwave. Distilled 
water could be used as the antigen retrieval solution with slight less effect 
(84)
.  
Shi et al in 1991 introduced the use of microwave in the technique of 
antigen retrieval, but the use of heavy metals posed significant difficulties 
and problems. Later in 1992 Gerdes performed antigen retrieval with non 
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toxic citrate buffer. Cottoretti in 1993 argued that microwave antigen 
retrieval is an alternative to proteolytic enzymes. Various problems 
including uneven heating and hot spot production are the important 
problems with the use of microwave. 
In 1994, Norton suggested the use of pressure cooker method for 
antigen retrieval. It is considered as one of the suitable method as it 
produces even heating and has no disadvantages which includes hot spot 
and cold spot production which often occur with the use of microwave. 
Streamer antigen retrieval is less efficient when compared to microwave and 
pressure cooker. Kawai in 1994 showed that water bath set at 90
0
C is 
adequate for antigen retrieval. However, quality of antigen retrieval 
improves with increase in the temperature to 95-98
0
C.   
Evers and Nylings
(101)
in his study found that antigen retrieval depends 
on both pH and temperature. They concluded that it is not important what 
kind of solution is used as long as the pH is appropriate. Chemical 
composition and the molarity of the antigen retrieval solution may act as a 
cofactor for effectiveness of antigen retrieval and hence 
immunohistochemistry. 
Non specific background staining 
Non specific staining in immunohistochemistry is attributed to non 
specific antibody binding and action of endogenous enzymes. Non specific 
staining is more common with usage of polyclonal antibody because of 
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multiple unwanted antibodies. Blocking of endogenous enzymes activity is 
important. The degree of susceptibility of an enzyme to denaturation and 
inactivation varies from tissues to tissues. Any residual activity of 
endogenous enzymes must be abolished. Endogenous peroxidase activity is 
seen in neoplastic cells, erythrocytes, neutrophils, eosinophils, and 
hepatocytes.  Usage of various substances for blocking endogenous 
peroxidase is suggested. 
Some investigators thought that use of methanol-hydrogen peroxide 
may cause denaturation of antigen. Strans
(102,103)
 advocated the use of 
phenylhydrazine by combination of phenyl hydrazine, nascent hydrogen 
peroxide and sodium azide. Mixture of hydrogen peroxide and sodium azide 
was found to be very effective
(104)
. More recently cyclopropane hydrate was 
shown to inhibit endogenous activity without adverse effect
(105)
. 
Endogenous alkaline phosphatase activity is usually blocked by addition of 
Levamisole to the substrate. Levamisole selectively inhibits certain types of 
alkaline phosphatase but not intestinal and placental. 20% glacial acetic acid 
is a better alternative to levamisole.  
IMMUNOHISTOCHEMISTRY AND NHL 
The use of antibody panels in immunohistochemistry is well 
accepted. Single antibody directed against the malignant cells will not serve 
for the diagnosis and is insufficient. We need to use panel of markers to 
differentiate one form of Non-Hodgkin lymphoma from the others 
(106,107)
. 
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Much of the early work in diagnostic hematopathology required frozen 
section or acetone fixed frozen section as available antibodies failed to 
recognize the antigens fixed by cross linking fixatives. Partial enzyme 
digestion gives good result
(108)
.   
Understanding of the development, maturation and migration of 
lymphocytes provides rationale for immunophenotyping because stages in 
lymphocyte maturation are defined in part by the macromolecules they 
produce. Malignant cells expresses antigen that resembles the antigens of 
lymphocytes in different developmental stages. Lymphomas are thought of 
as being composed of cells arrested in development of certain stages
(109)
. 
Hence the panel of markers directed against the malignant cells will be of 
more help.    
Immunohistochemical markers are selected based upon the 
morphology. Morphological assessment takes into account the architectural 
alteration in B-cell zone and T-cell zone. The markers include leucocyte 
common antigen, B-cell markers such as CD20 and CD79a, T-cell markers 
like CD3 and CD5 and other markers including CD23, bcl-2, CD10, 
cyclinD1, CD15, CD30, ALK-1 and CD138. Currently there are more than 
50 antibodies which are used in the diagnosis of Non-Hodgkin lymphoma. 
Explosion of antigens and reagents to detect them needs judicious use of 
selected panel of markers. It should always be noted that no antigens is 
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totally specific and therefore needs careful selection of panel of markers to 
arrive at proper diagnosis. 
LYMPHOMA DIAGNOSIS 
The diagnosis of lymphoma is based on the World health organisation 
classification 
(110)
(2008). Further classification is based on the stage of 
maturation and cell of origin. Other features which help in the diagnosis are 
anatomic architectural alteration in the lymphoid compartment, 
determination of cell size, nuclear character, and character of nucleoli. 
B-cell markers 
CD20 is the most common antibody used as the pan-B cell marker 
and is expressed by naive B cell until the final stages of  maturation just 
prior to plasmacytic differentiation. Chronic lymphocytic lymphoma/small 
lymphocytic lymphoma rarely shows weak positivity
(111)
 to CD20. In cases 
of prior rituximab therapy, CD79a should be added. Early stage including 
naive cells and other B-cell expresses Pax-5 but not the plasma cells
(112)
. 
Few cases of precursor T-cell acute lymphoblastic lymphoma expresses 
CD79a and rare cases of AML and merkel cell carcinoma shows positive 
expression of Pax-5.  
When B-cell follicles are not well made under histopathology the 
immunohistochemical markers like CD21, CD23 and CD35 may be helpful 
in highlighting follicular dendritic cells. Staining the sections for kappa and 
lambda light chains may be useful in detecting the abnormal clonal 
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population, especially plasma cells. Immunohistochemistry although less 
sensitive in the detection of immunoglobulin expression, can be more 
valuable when used along with histopathology. Plasma cells and 
immunoblast shows strong expression of immunoglobulins which can be 
detected by paraffin immunoperoxidase method. Calorimetric insitu 
hybridisation is an alternate and most sensitive method used in the detection 
of immunoglobulin.  
T-cell markers 
CD3 is the most commonly used pan-T cell marker which detect the 
antigenic expression over the malignant and normal T-cell at the second 
stage of thymic differentiation and beyond. Sometimes there may be loss of 
pan-T cell marker over the malignant lymphoid cells as in case of anaplastic 
large cell lymphoma
(113)
. T cells are divided into CD4 and CD8 subsets. 
Antibodies directed against these antigens are used as basic panels to detect 
abnormal distribution of lymphoid cells. CD5 is another pan-Tcell marker 
which is lineage non-specific and is not expressed on Natural killer cells. 
CD5 is present over small subset of B-cells especially among the cases of 
chronic lymphocytic lymphoma, mantle cell lymphoma.  
Atypical cells and Lymphoma 
Histopathological examination of some lymphomas may show many 
large atypical lymphoid cells admixed with other similar looking lymphoma 
cells. When there is presence of large atypical cells, the possibilities of 
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carcinomas, Hodgkin lymphoma and anaplastic large cell lymphoma should 
be ruled out. This is done by using a panel of markers including CD45, 
CD15, CD30 and HMB45. The usage of antibody directed against ALK-1 
may prove more valuable.  
Other antibodies 
Several other markers have found application in the diagnosis of Non-
Hodgkin lymphoma. These include CD10, Bcl-6, cyclin D1, Bcl-2, CD56 
and CD57. CD10 and Bcl-6 are the markers that show positive expression in 
normal and neoplastic follicular centres. CD10 also show positive 
expression on granulocytes, T-cells in angioimmunoblastic 
lymphadenopathy, precursor B-cells and T-cells, epithelial cell neoplasms 
like renal cell carcinomas, hepatocellular carcinomas and endometrial 
stromal cells. Bcl-6 is expressed in follicular centres and few T-cells. The 
presence of CD10 positive lymphocytes along with Bcl-6 positive cells 
outside the follicles strongly suggests neoplastic proliferation. But rare cases 
of follicular lymphoma which shows negative expression of CD10 have 
been recorded.  
Bcl-2 is an antiapoptotic molecule which is normally expressed over 
pre-B cells, and resting B-cells of normal mantle zone and in rare cases with 
proliferating B-cells. Most of the neoplasms composed of small lymphoid 
cells usually show positive expression of Bcl-2
(114)
 and expression of Bcl-2 
is downregulated in normal follicles. B-cells in reactive follicles show 
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negative expression of Bcl-2 and there is strong expression of Bcl-2 in 
lymphoid cells of mantle zone and cells of primary follicle
(115)
. The 
interpretation of Bcl-2 should be carried out in conjunction with CD3 
staining for T-cells as T-cells normally show positive expression of Bcl-2. 
Most of the cases of marginal zone lymphoma shows Bcl-2 expression but 
reactive hyperplastic marginal zones of spleen and lymph nodes of abdomen 
also show Bcl-2 positivity. CyclinD1 is another immunohistochemical 
marker which has gained its importance in the diagnosis of Mantle cell 
lymphoma. Cyclin D1 is normally expressed in endothelium, nucleus of 
histiocytes, and fibroblast. It is usually expressed in the nucleus of lymphoid 
cells of mantle cell lymphoma. Cytoplasmic expression is considered non 
diagnostic. Although nuclear expression of CyclinD1 is almost diagnostic of 
mantle cell lymphoma many cases of CyclinD1 negative mantle cell 
lymphomas are on the records and even CyclinD1expression has been 
recorded in many cases of small lymphocytic lymphoma. 
Immunohistochemical markers like CD56 and CD57 play important role in 
the diagnosis of natural killer cell proliferation and neoplasms arising from 
natural killer cells.   
PANEL OF MARKERS FOR NON HODGKIN LYMPHOMA 
Lynette  K Tumwine et al 
(116)
, studied the expression of B cell 
antigens in 119 Non Hodgkin lymphoma patients using a panel of 
CD3,5,10,20,23,30,38,79a,138, bcl-2, MUM1/IRF4, cyclinD1 and Ki-
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67/Mib1 antibodies. They found 100% positivity for CD20 in DLBCL and 
Burkitt lymphoma patients. Among DLBCL patients, 10.5% positivity was 
seen for bcl6, 22.2% positivity for MUM1/IRF4 and 66.7% for CD138. 
According to I.Satish Rao
(1)
 distinction of monomorphic small B cell 
lymphomas are done by basic panel of markers such as CD5, 23, 10, cyclin 
D1 and bcl2, intermediate cells with diffuse pattern by markers such as 
CD20,10, Tdt, CD99 and Mib1 and large cells with diffuse pattern by 
CD20, CD79a, CD138 and EBER.   Nirmala Ajit Jambhekar  et al 
(117)
 
suggests a panel of markers for Non Hodgkin lymphoma diagnosis which 
includes CD20 which is a B-cell marker showing membrane staining, CD3 
is a T-cell marker, CD21/CD35 stains follicular dendritic cells and hence 
are useful to demonstrate germinal centers within the lymphoid 
proliferation, CD5 which detects B-cell CLL/SLL and mantle cell 
lymphomas. CD23 shows positivity for B-CLL/SLL, whereas it is negative 
in mantle cell lymphoma. Mantle cell lymphoma shows immunoreactivity to 
Cyclin D1. Alk-1 is specific for anaplastic large cell lymphomas (ALCL) 
which also shows CD30 positivity and focal EMA positivity. Bcl-2 is useful 
in distinguishing reactive follicles (negative) from follicles of follicular 
NHL (positive) whereas CD10 is positive in Burkitts lymphoma. 
                Kwak LW and Wilson M 
(118) 
in their study found out that among 
all the cases of DLBCL, 65% to 85% are of B cell type and 15%-35% are T 
cell type. T cell rich variant of DLBCL may show membranous staining of 
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pan T cell marker (CD3). Hans et al 
(119)
 in their study on 152 cases of 
DLBCL demonstrated the expression of CD10 in 28% of cases, bcl-6 in 
56%, MUM1 in 47%, bcl-2 in 50%, cyclin D2 in 13% and FOXP1 in 61% 
of cases. Ting Li et al 
(120) 
studied immunohistochemical features in 63 cases 
which resulted in expression of CD10 in 30% of cases, bcl6 in 35% and 
MUM1 in 51% of cases. 
Strauchen JA and Mandeli JP 
(121)
 in their study of 345 cases of B cell 
NHL found Ig expression in 59% cases of large cell lymphoma and 100% of 
small cell lymphoma. Picker LJ et al 
(122)
 documented that immunoblastic 
variant especially those with plasmablastic differentiation showed 
cytoplasmic Ig expression. Piris M et al 
(123) 
through their study suggested 
that most of the anaplastic variant showed positive membrane staining for 
CD30. Fang JM et al 
(124)
 found that 20-30% of DLBCL showed CD10 
positivity. 
          Follicular lymphoma cells show positive membrane staining for CD 
19, 20, 22 & 79a with typical surface monoclonal Ig expression. Jaffe ES et 
al 
(29) 
through their study found out that follicular lymphoma cells do not 
express CD3, 5 and 23. Both follicular and inter follicular zones contain κ or 
λ clonally restricted B cell. Lai R et al (125) in their study found that 
malignant cells were negative for CD43. Gaulard P et al 
(126) 
demonstrated 
overexpression of nuclear positivity for bcl-2 in germinal centre among the 
cases of low grade follicular lymphoma.  
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           Robert R. Lorsbach et al 
(127)
 through their study on 19 paediatric 
follicular lymphoma patients showed CD20 and bcl6 positivity in all cases 
and CD10 positivity in 80% of cases. Andrew J Davies et al 
(128)
 observed 
through their study that among the follicular lymphoma patients assessed for 
transformation to DLBCL, 89% showed germinal centre phenotype with 
CD10
+
, bcl6
+
, and MUM1
- 
. Follicular lymphoma in addition to mimicking 
the growth pattern of reactive follicles, contain non neoplastic T cells and 
follicular dendritic reticulum cells. According to Said JW et al 
(129)
 follicular 
dendritic reticulum cells in follicular lymphoma and reactive follicular 
hyperplasia express CD21 and CD35 whereas follicular dendritic reticulum 
cells in follicular lymphoma but not in reactive follicular hyperplasia, lack 
the expression of fascin.  
In mantle cell lymphoma, the neoplastic cells show membranous 
positive expression of CD19, 20, 22, 79a and CD5. Vasef MA 
(130) 
and   
Cheuk W 
(131)
 through their study showed that almost all the cases of mantle 
cell lymphoma showed strong nuclear expression for cyclin D1. In case of 
CLL/SLL, the cells are B cells with positivity for surface Ig light chain, 
IgM, IgD, pan B cell antigens, CD5 and 23 antigens.  
According to Williamze R et al 
(132)
 the cells of mycosis fungoides 
and Sezary syndrome have a mature T cell phenotype and are of T helper 
cell lineage. These cells express pan T cell antigens CD2,3,5 and CD45 RO. 
Picker LJ et al 
( 133) 
in their study showed that PTCL cells express 
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CD2,3,CD5 and 7,43 and CD45RO but are negative for B cell antigens. 
Through their study Rudiger et al 
(134)
 showed that AITL express antigens 
like CD10, bcl6, CXCL13, SAP, programmed death-1 and activation 
induced cytidinedeaminase. In cases of anaplastic large cell lymphoma, 
ALK
+
 anaplastic large cell lymphoma by definition shows ALK positivity 
and CD30 expression in a distinctive pattern along with expression of T cell 
antigens. 
            According to Afaf Abdel-Aziz, Abdel-Ghafar
(135)
 the grading of 
immunohistochemical staining can be done using percentage of positive 
cells which include four grades, 0: no reaction, 1+: <5%, 2+: 5–9%, 3+: 10–
20% and 4+: ≥20%. 
OTHER MODALITIES OF DIAGNOSIS OF LYMPHOMA 
Ultrastructural examination is not routinely done in the identification 
of lymph node lesions, but it is inexpensive to fix the sample in 
glutaraldehyde which can be used later, if needed. Electron microscopy is 
useful in rare disorders which include storage disorder like Gaucher‘s 
disease, lymphoblastic lymphoma, mycosis fungoides and amyloidosis. 
Immune electron microscopy can be helpful to study the cell surface 
markers and immunoglobulins after applying peroxidase labelled antibodies. 
Ultrastructure is more useful in identifying metastatic deposits in lymph 
nodes especially in the cases of malignant melanomas demonstrating 
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melanosomes
(136), Ewing‘s sarcoma with abundant glycogen(137) and small 
cell carcinomas with neurosecretory granules
(138)
. 
 Chronic lymphocytic lymphomas are characterised by increased 
synthesis of immunoglobulin light chain when compared to heavy chain. 
Ultrastructural examination in such cases reveals Ig light chain in both 
perinuclear space and rough endoplasmic reticulum whereas heavy chains 
are limited to rough endoplasmic reticulum.  
Lymphoblastic lymphoma under electron microscope shows round 
cells with a high nuclear to cytoplasmic ratio with convoluted nucleus 
showing deep indentation and fine chromatin with peripheral nucleolus 
(139)
. 
The examination of angioimmunoblastic lymphoma shows nuclear 
indentation, speckled heterochromatin and prominent nucleolus 
(140)
. 
 The diagnosis of lymphoma, as proposed by WHO, now primarily 
depends on imunophenotyping. Immunophenotyping is usually performed 
by using IHC and flow cytometry. Flow cytometry has many advantages 
over IHC and is usually performed in higher centres. It is a qualitative 
analysis of antigen expression which determines the density of more than 
one antigenic expression simultaneously by using many fluorochromes per 
test tube. Hence, it can be easily standardised and also has a rapid turnover 
time. The main disadvantage of flow cytometry is it can be performed only 
in fresh living tissues. 
53 
 
             Molecular diagnosis is considered as gold standard 
(141,142)
 in 
assessing monoclonality and chromosomal translocations. Unlike 
immunohistochemistry which detects proteins, molecular diagnosis detects 
DNA of genes encoding immunoglobulins and T cell receptor. Various 
techniques used in routine practice are conventional cytogenetics, southern 
blot technique, polymerase chain reaction and fluorescence insitu 
hybridisation. Polymerase chain reaction is a versatile technique used in the 
analysis of clonality, chromosomal translocation, genetic mutation, 
infectious agents and minimal residual disease. The main disadvantage is 
the occurrence of false positivity because of its high sensitivity. 
 
          Chromosomal translocation plays an important role in the occurrence 
of many lymphomas and hence identification of such translocation proves 
the diagnosis. This is carried out often using conventional cytogenetics or 
florescence insitu hybridisation technique. This can identify wide range of 
translocations which includes myc translocation in Burkitt‘s lymphoma(143), 
t(11;14) involving cyclinD1 in mantle cell lymphoma
(144)
, t(14;18) involving 
Bcl2 gene in follicular lymphoma, Bcl6 in case of diffuse large B-cell 
lymphoma and subset of follicular lymphoma
(145)
 , ALK translocation as in 
the case of anaplastic large cell lymphoma, t(1;14) (11;18)(14;18) in  
MALT lymphomas and t(11;14)(4;14) as in case of myeloma.      
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CONDITIONS MIMICKING LYMPHOMA 
               Reactive lymphoid hyperplasia is defined as a benign reversible 
process characterised by proliferation of reactive lymphoid cells in various 
pattern secondary to antigenic stimulation. Clinically, this condition is 
manifested as enlarged lymph nodes in multiple sites including cervical 
nodes which are often affected in infectious mononucleosis, posterior 
cervical group as in the case of toxoplasmosis, axillary node in cat- scratch 
disease, parotid, submaxillary and epitrochlear group as in the case of HIV 
infection. When there is involvement of supraclavicular lymph nodes 
careful evaluation of the patient including age, sex, family history, 
symptoms and signs are performed. This is because these nodes are 
associated with either primary or metastatic malignancy in 25% of patients 
younger than 40 years and 90% of patients older than 40 years. 
(146) 
 
Reactive lymphoid hyperplasia can be caused by various bacterial and 
viral infections, exposure to chemical substances and environmental 
pollution, drugs and numerous allergens. Among the drugs phenytoin, 
penicillins, gold and quinidine play a major role
(147)
. Reactive lymphoid 
hyperplasia, occur most commonly in children and younger age group. 
Hyperplastic nodes are less common among the elderly because of the 
decreased humoral immune response 
(148)
 and hence the proliferation of 
germinal centre is less apparent than in young patients 
(149)
. 
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 Most of the hyperplastic nodes show nonspecific pattern. But 
characteristic morphological pattern can be seen in reactive follicular 
hyperplasia secondary to activated humoral immune response, diffuse 
paracortical hyperplasia as in the case of viral lymphadenitis and sinus 
histiocytosis. Histopathology of reactive follicular hyperplasia is 
characterised by numerous reactive secondary follicles of varying size and 
shape distributed in the cortex and medullary region, with well demarcated 
mantle cell zone. The germinal centre comprises mixture of small and large 
lymphoid cells. 
 The presence of numerous follicles throughout the cortical and 
medullary zones makes morphological distinction of exaggerated follicular 
hyperplasia from follicular lymphoma. However, according to Nathwani
(150)
, 
numerous back to back follicles with even distribution of the cortex and 
medulla with scant inter-follicular area in addition with cytological features 
helps in the distinction. But in more difficult cases, immunohistochemistry 
may prove useful. 
Diffuse paracortical hyperplasia is characterised by expansion of 
paracortical area due to increase in number of reactive T cells containing 
mixture of small cells and activated large cells, the immunoblast. 
Immunoblasts are larger cells with scant cytoplasm, large nucleus and 
prominent nucleoli resembling Hodgkin and RS cell 
(151)
 and rarely 
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metastatic deposit from amelanotic melanoma. In difficult cases like this, 
immunohistochemistry solves the problem. 
Atypical lymphoid hyperplasia is a group of disorder that is neither 
benign nor malignant which occurs in cases of primary immunodeficiency. 
This disorder occupies an intermediate position between reactive lymphoid 
hyperplasia and malignant lymphoma. The morphology is characterised by 
nodular or diffuse proliferation of lymphoid follicles admixed with many 
atypical large cells with large nucleus and prominent nucleoli. These 
atypical cells can be either singly scattered or in sheets, and when so can 
cause difficulties in differentiating it from malignant lymphomas and 
metastatic deposit. In such cases immunostaining to demonstrate 
monoclonal light chain (either κ or λ) is necessary. 
Some of the drugs that are used for therapy, either in shorter term or 
after a longer period of time, can produce generalised lymph node 
enlargement mimicking malignant lymphoma. But these can be 
differentiated from true cases of malignant lymphoma by the regression of 
the lymph nodes after discontinuation of the drugs. This is called as 
anticonvulsant hypersensitivity syndrome as such cases can occur after the 
use of phenytoin and carbamazepine. This syndrome is found to have 
genetic predisposition which can be attributed to inherited defects in the 
epoxide dehydrolase 
(152)
 which detoxifies epoxide hydrolase formed as a 
result of metaboloism of phenytoin and carbamazepine by cytochrome 
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p450. Gennis estimated that pseudolymphoma after phenytoin therapy 
occurs in the range of 1:1000. Anticonvulsant hypersensitivity syndrome 
(pseudolymphoma) occurs in association with haematological abnormalities 
such as eosinophilia, leucocytosis/ leucopenia and atypical lymphocytosis.  
This is manifested as acute increase in the size of the lymph nodes 
with effaced nodal architecture but preservation of atleast portion of lymph 
node can be usually seen.  Histopathologically, this is characetrised by 
paracortical expansion with rarely follicular hyperplasia. Paracortical 
expansion is characterised by proliferation of mixed inflammatory cell 
infiltrates composed of eosinophils, small lymphoid cells and large atypical 
looking immunoblast. Hence it should not be confused with malignant 
lymphomas including Hodgkin and Non-Hodgkin lymphomas especially T-
cell lymphomas like anaplastic large cell lymphoma and 
angioimmunoblastic lymphomas. In case of difficulties 
immunohistochemistry, flow cytometry, PCR or molecular diagnostic 
approaches will be useful. The absence of monoclonal gene rearrangement 
favors drug associated lymphadenopathy over true malignant lymphomas. 
(153,154)
 
 
 
 
 
58 
 
DRUGS CAUSING LYMPHADENOPATHY 
Phenytoin 
Carbamazepine 
Phenobarbitol 
Gabapentin 
Lamotrigine 
Penicillin 
Gentamicin 
Allopurinol 
Methyldopa 
Aspirin 
Phenylbutazone 
Primidone 
Methimazole 
Quinidine 
Tetracycline 
Ethosuximide 
Halothane 
Mexiletine 
Abacavir 
Ivermectin 
Gold 
Iron dextran 
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LYMPHNODE AND NECROSIS 
            Necrosis in the lymph node can be focal or diffuse replacing the 
nodal architecture. It can be of any type which includes coagulative, caseous 
and fibrinoid type. Caseous necrosis most commonly occurs in infections 
like tuberculosis in which the necrotic areas appear granular and eosiniphilic 
surrounded by epithiloid cell granulomas, lymphocytes and fibroblasts. In 
addition, the disease causing organisms can be demonstrated in such kind of 
lesions. 
Fibrinoid necrosis can occur in the cases of vasculitis involving the 
lymph node. Apart from this, histiocytic necrotising lymphadenitis also 
called Kikuchi-fujimotos lymphadenopathy is characterised by patchy or 
confluent areas of fibrinoid material with necrotic debris surrounded by 
histiocytic proliferation. Some cases rarely show scattered cells with 
karyorrhexis and pyknosis
(155)
. The periphery of the necrosis is characterised 
by thrombosed vessels, and nests of plasma cells, monocytes and 
immunoblast. Some of these cells are atypical and can be mistaken for 
lymphoma. The histiocytes which phagocytosed nuclear debris have 
peripherally placed crescentic nucleus and hence can be mistaken for signet 
ring cell carcinoma deposit. But importantly, absence of neutrophils and 
eosinophils are the distinct morphological feature of Kikuchi-Fujimoto 
disease. 
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Lymph nodes are organs with rich vascularity and hence rarely 
infracted. However, cases of coagulative necrosis involving most of the 
nodal parenchyma, sparing only a narrow subcapsular rim have been 
recorded
 (156, 157)
. The causes include occlusive vascular thrombosis, 
thrombophlebitis, localised trauma secondary to fine needle aspiration and 
as a secondary complication to surgical procedure. Coagulative necrosis can 
occur secondary to malignant lymphomas. This may be due to expansion of 
lymphomas causing pressure effects over the vessels or due to direct 
invasion of the hilar vessels. Hence massive infarction should always be 
viewed with a suspicion of underlying malignancy. The demonstration of 
preserved antigen in the necrotic area through immune histochemistry is 
useful in such situations.  
           Castleman‘s disease is defined as the large benign asymptomatic 
lymphadenopathy usually involving mediastinal groups. The cause for 
Castleman lymphadenopathy is not known, however HHV-8 is considered 
to be a known etiological agent. Primarily two variants has been described 
namely hyaline vascular and plasma cell variant which can be unicentric or 
multicentric. The hyaline vascular variant is by far the most common variant 
(158,159)
. Histologically it is characterised by changes in the follicular and 
interfollicular area. Within the follicles there may be twinning of germinal 
centres with reduced number of small lymphoid cells. The blood vessels are 
arranged radially and there may be deposition of hyaline material in the 
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centre of the vessels. The expansion of mantle zone is observed with small 
lymphoid cells arranged concentrically in an onion-skin fashion. The 
interfollicular area shows mixed population of cells. 
The plasma cell variant is characterised by sheets of plasmablasts and 
mature plasma cells expanding the interfollicular area. 
Immunohistochemical evaluation is needed when there is florid proliferation 
of these cells leading to confusion with lymphocytic lymphoma and plasma 
cell neoplasm. 
TISSUE MICROARRAY  
Tissue microarray is a method which is used to evaluate numerous 
samples in a short period of time. Tissue microarray allows for high-
throughput molecular profiling of tissue specimens by a number of 
techniques including immunohistochemistry
(160)
. Tissue microarray is very 
useful in investigating a large number of different molecules involved in 
solid tumour development
(161)
.  TMA are very useful tools for rapid and 
efficient analysis of large number of paraffin embedded tissue sections
144 
and a revolutionizing approach to allow multiplex histological analysis. This 
technique is now widely used in the analysis of a many number of 
biomarkers 
(162)
 and are used as a tool in the diagnosis of a variety of 
infections
(163)
. However, the use of Tissue microarray as a tool of quality 
control of diagnostic staining has been advocated in recent years. 
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The origin of Tissue microarray technique is attributed to Dr. Hector 
Battifora‘s sausage block technique(164) which he introduced in 1986 in 
which a number of tissues from various organs are thrown into the same 
block and tissue distribution of particular antigen was processed. The idea 
of Battifora was later redefined by Wan et al
(165)
 who produced a library of 
paraffin embedded cores and used it to determine various staining patterns 
of many number of monoclonal antibodies. Wan et al in his technique used 
16 gauge needle to manually bore cores from tissue blocks and array them 
in recognisable pattern. Later this was modified by Kononen et al
(160)
 who 
introduced the term ‗Tissue microarray‘ in 1998 which is widely used 
nowadays, which includes the usage of 4mm skin biopsy punch.  
 
 
 
 
 
 
 
 
 
 
 
63 
 
 
 
 
 
 
 
Figure 3
(166)
: Low magnification picture of an H&E stained TMA section 
that was cut from a TMA block                                    
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Figure 4
(167)
:  Beecher Instruments Tissue Arrayer 
This picture shows the view of the front of the machine with recipient block 
in block holder which is attached to the rest of the machine via a magnet. 
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Materials for TMA 
The source of the material for construction of Tissue microarray 
varies widely. Tissue microarrays are categorised based on material of 
origin. They are called simply as Tissue microarray when they are 
constructed from paraffin embedded materials. Tissue microarrays can also 
be constructed using resin as recipient block, if very thin sections are 
required. But the construction of resin Tissue microarray is very difficult 
when compared to paraffin Tissue microarray
(168)
.Tissue microarrays can 
also be constructed using frozen sections in which case they are called as 
Cryoarrays
(169)
or can be constructed using paraffin embedded cell lines and 
by using cell blocks
(170)
. 
TMA categorisation 
Tissue microarray is categorised based upon the usage of instruments 
and purpose of tissue microarray. Based upon the usage of the instruments 
and microarrayer used it has been classified into manual, semi-automated 
and automated tissue microarray. There are many instruments which are 
available nowadays which includes, the manual and automated tissue 
arrayer from beecher instruments, the semi-automated tissue arrayer from 
veridiam, the quick ray manual and the automated tissue arrayer from 
unitma and the manual arraymold tissue arrayer. Apart from this many 
number of home- made tissue arraying methods have been published
(171)
.   
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The common feature between all these devices is that they use hollow 
needles or punches and they adopt the technique of skin biopsy to extract 
tissue cores from a donor block and make a new paraffin recipient block. 
After cutting all the tissue cores appear as circular samples arranged in grid 
like fashion. 
The initial step which is considered most important in construction of 
Tissue microarray is to clearly define the purpose of Tissue microarray 
construction and to decide the number and size of the tissue core which 
should be taken from the donor block. Then blocks and slides of the selected 
cases are carefully reviewed to mark the area of interest. The method of 
tissue sampling varies widely from tissue to tissue. If task is to compare the 
expression pattern of a marker from tumour centre and periphery, the cores 
from the particular location may be compatible. However the method of 
tissue sampling is entirely different when the task is to characterise the 
overall expression of the protein in a tumour. Targeted sampling technique 
is followed in the cases of comparing the expression patterns of tumour 
centre and periphery whereas Random sampling technique is best suited to 
study the overall expression patterns
(172)
.  
 Tumour heterogeneity, which results in differential expression of in 
different tumourcell has been recognised as the potential problem in tissue 
sampling for the construction of Tissue microarray 
(173)
. Taking multiple 
samples from each tumour or area of interest appears to be the best 
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technique to overcome this problem. Although no standard and universally 
agreed sampling methods are in the records, it is intuitive that the more 
samples are taken it becomes the representative area for donor tissue. The 
concordance of Tissue microarray technique with full section eventually 
depends upon the number of cores obtained. Most of the studies seem to 
indicate that the results from triplicate Tissue microarray cores have upto 
98% concordance with the results from full section
(174)
. However Goethal 
through his study suggests that atleast four cores are needed to achieve 
greater accuracy, whereas others achieved 95% accuracy with only two 
cores 
(175)
.  
It should be also noted that there are also technical reasons which 
increases number of cores taken from each tissue block. The reasons are 
tissue folding and complete loss of tissues during processing and section 
cutting. Total number of lost cases accounts for as high as 23% in the Tissue 
microarray construction study by using tissue cores from the cases of renal 
cell carcinoma
(176)
. There are controversial data regarding the size of the 
cores that should be used in Tissue microarray technique and their influence 
over the technique. 
The next critical step included in tissue microarray is designing the 
layout of the tissue microarray. There are no general agreements regarding 
the designing of optimal layout of a tissue microarray. As there are 
problems of staining artifacts when performing immunohistochemistry in 
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the full sections, the use of protection wall in the Tissue array technique is 
recommended as introduced by Hoose et al, which uses a row of tissue cores 
which will not be analysed and can be any tissue that is available in plenty 
in the laboratory. Any confusion in identifying the origin of the cores after 
Tissue microarray construction makes the staining and analysis very 
difficult and hence orientation of the tissue cores needs to be perfect. Many 
use orientation cores in the specific position, usually outside the geometric 
margin of the array. Using the intentionally left empty core position, it is 
possible to identify and orient the position of the cores macroscopically as 
well as to orient cut section microscopically. In addition insertion of control 
tissue array may be of more value in orientation of the tissue cores. Thus the 
control core serves as an orientation control and also as both internal 
positive and negative control.  
Recipient blocks are nothing but the empty paraffin blocks that are 
prepared by pouring the soft molten wax into existing metal moulds of 
varying size. The major difficulty encountered in using metal moulds is the 
formation of air bubbles within the recipient blocks during the cooling 
procedure. The air bubbles which are formed during the process of cooling 
will not be evident apparently and not be identified till the section cutting. 
The subsequent sectioning of Tissue microarray causes severe distortion of 
constructed array and leads to difficulties during the steps of interpretation 
and analysis. To minimise this kind of problem and as a quality control 
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measure, all the recipient blocks are subjected to X-ray by using Faxitron 
machine before Tissue microarray construction and if air bubbles are found 
the recipient blocks are melted for reuse. The use of moulds which are made 
from paper and plastic may reduce the problem of bubble formation which 
is commonly encountered when paraffin recipient blocks are used. 
Tissue Arrayers 
Both automated and manual tissue arrayers are available for the 
construction of Tissue microarray. Automated tissue arrayers are easy to 
use. The instrument usually marks, edits and saves punch co-ordinates by 
using an on screen display and software tools. Automated tissue arraying 
instruments are commonly used in laboratories with high volume of Tissue 
microarray and can punch upto 180 cores/hour. 
Automated HT-1tissue microarray 
Automated Tissue microarray is a highly potential and efficient 
technique which can be used to study gene expression. At present TMA has 
become a standard research platform for the histopathological analysis .This 
technique involves the acquisition of multiple core biopsies from area of 
interest from the donor block and transferring it into the recipient paraffin 
blocks with the help of special instrument. This includes collection and 
selection of donor blocks to be analysed, identifying the area of interest and 
representative areas, preparation and making array pores in the recipient 
paraffin blocks, punching tissue cylinders from the area of interest from the 
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donor block, insertion of  cylinders containing tissues into the recipient 
blocks and embedding and cutting of newly formed Tissue microarray. 
However most important of all these steps is the construction of tissue 
microarray blocks using commercially available instruments. The key steps 
in automated tissue microarray are punching array pores in recipient blocks 
and embedding multi-tissue cylinders into the recipient blocks. 
Recipient block formation 
This method uses three types of recipient block maker which are 
called as recipient block-molding machine  that can accommodate 24, 42, 56 
tissue cylinders . The spacing between the cores is usually fixed. Recipient 
paraffin blocks can be made within several seconds by using block-molding 
machine. The instrument is composed of an array pores forming metal tamp, 
series of metal embedding boxes and punch needles with corresponding 
inner cores. The array pores-metal consist of metal plates and a bracket. The 
lower plate is fixed with hollow cores while upper plate is fixed with inner 
cores. The inner diameter is designed from 0.5 to 2.5mm.The instrument for 
making array recipient blocks is fixed in the manipulator with the help of 
the bracket. The lower plate with the hollow array can move up and down 
by controlling the handle. The residual paraffin in array hollow punch is 
automatically removed by the piston.  
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Negative-pressure embedding 
Negative pressure embedding instrument is designed to re-embed the 
multi-tissue cylinders into the recipient block for the construction of Tisssue 
microarray. It is composed of negative pressure room, vacuum pump and a 
embedding box. The embedding box is situated in the negative pressure 
room and is connected to the vacuum pump through the tube. The bottom of 
the embedding box consists of metal mesh, which can effectively adjust the 
negative pressure so that the air bubbles which are formed can be drained 
out of recipient paraffin blocks. Screen mesh can also be used to adjust the 
temperature for the embedding media. 
TMA without prefabricated recipient block 
Array construction done with the help of automated tissue arrayers 
proved to be very costly and hence not suitable in developing laboratories. 
Hence efficient microarray system which is cost effective was designed 
using manual tissue arrayer technique. Most of the manual methods used 
preconstructed paraffin recipient block into which holes are punched 
followed by insertion of tissue cores. The use of paraffin blocks proved 
difficult because of block breakage during punching, non alignment of 
holes, and mismatch between the size of the recipient hole and the tissue 
core. With the desire to overcome these difficulties, TMA construction was 
done without the use of prefabricated paraffin blocks.  
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This technique followed the method which was initially modified by 
Kononen et al. A disposable skin punch biopsy needle of 2mm diameter was 
used for punching cores from the donor blocks. A long steel wire with a 
blunt end was modified into a stylet. The skin biopsy needle has the sharp 
cutting edge and a uniform cylindrical core. Double sided adhesive tapes, 
pair of stainless steel forceps, paper cutters, embedding mould and plastic 
cassettes are the requirements of this technique. A piece of double sided 
adhesive tape is cut according to the size of embedding mould and the top 
surface is exposed to receive the tissue cores. The site for the attachment is 
marked with the ruler and the felt pen. The area to be cored is marked on the 
block by superimposing the marked area over the slides. After obtaining the 
core from the donor block, the core is transferred to adhesive tape using the 
forceps. Then it is transferred to stainless steel mould and after which 
melted paraffin wax is poured. Later after uniform setting of the block the 
adhesive tape is peeled off to expose the cutting surface. This method can 
give rise upto 20sections from each core. This is reliable, readily 
reproducible and does not need any specialisation.  
Simple manual tissue microarray 
This is the modification of conventional manual tissue microarray 
which used skin punch biopsy needle. This technique used bone marrow 
aspiration needle for the construction of manual tissue microarray. Both 14 
gauge and 16 gauge needles are used. After the selection of donor block, the 
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area of interest is marked and empty recipient paraffin block is made using 
the mould. By using 16gauge needle pores are made in the recipient block. 
Then with the help of 14 gauge needle tissue cores are obtained from the 
area of interest and then inserted into the recipient block. The smaller 
diameter (16G) of the needle used to punch the blank paraffin wax block 
allowed the bigger tissue cores (14G) to fit exactly into the blank 
(177)
. Once 
the array is complete hot liquid paraffin is poured over the array surface and 
the tissue cylinders are levelled with the blocks using a glass slide. Then the 
array is incubated at 60
0
c for 15 minutes after which array is chilled on ice.  
Types of TMA based on Application   
The technique of tissue microarray can be classified based on the 
purpose of Tissue microarray construction. Random arrays contain tissue 
from multiple sites including both tumoral and non-tumoral tissues. This is 
most widely used for monitoring the efficacy of the existing antibodies. Cell 
line arrays consist of normal and cancer cell lines that are grown in cultures. 
The main purpose of using this array is to analyse the utility of an antibody 
in detecting the proteins. Outcome based arrays are the most valuable and 
the most difficult to construct as they involve the collation of  tissues from 
the patients of same disease, those who were exposed to similar pattern of 
treatment and have been followed up for significant period. Progression 
arrays are used in analysis of role of proteins in the progression of cancer. 
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Tumor characteristic based array is constructed based on the given 
characteristics such as patient age and tumor grade. 
The use of tissue microarrays has its own advantage and 
disadvantage. Tissue microarray allows the performance of tissue based 
array such as immunohistochemical analysis, histochemistry and in situ 
hybridisation on a very large number of sample in a cost effective manner. 
Several different tissues from a number of patients can be examined in short 
period using TMA. Automated Tissue microarrayers are very quick and 
manual tissue arrays are simple to construct and cost effective. The major 
disadvantage of using Tissue microarray is that each tissue core obtained 
from the selected donor block represents only the fraction of the lesion. But 
this is overcome by taking multiple cores usually from various sites. Hence 
Tissue microarray can be considered as one of the superior and more 
advantageous technique used in studying tissue biology. 
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MATERIALS AND METHODS 
 
Study material includes 21 cases of Non Hodgkin lymphoma 
diagnosed in the Department of Pathology of Tirunelveli Medical College 
during a period of 3 years from 2012 to 2014. 
Inclusion criteria  
                All the cases of Non-Hodgkin lymphoma that were diagnosed by 
using Hematoxylin and Eosin stain and cases with a differential diagnosis of 
Non Hodgkin Lymphoma and cases where an IHC confirmation was 
requested. 
Exclusion criteria 
i. Inadequate lymph node sample. 
ii. Poorly processed material. 
iii. All the cases of Hodgkin lymphoma 
iv. All cases of extra-nodal Non Hodgkin Lymphoma 
Materials required 
1. Lay out for constructing Tissue microarray. 
2. Metal moulds and molten wax for preparing empty recipient paraffin 
block. 
3. Donor blocks which contain formalin fixed paraffin embedded tissue 
obtained from all the cases of Non-Hodgkin lymphoma. 
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4. Hematoxylin and eosin stained tissue sections made from the donor 
blocks. 
5. Black glass marking pen for marking area of interest. 
6. 16gauge bone marrow aspiration needle for making punches in the 
recipient block and 14gauge needle for obtaining core from the donor 
block. 
7. Microtome and incubator for obtaining tissue sections from area of 
interest and for baking the sections, respectively  
8. Postively charged slides for holding tissue sections for IHC. 
9. Chemicals for preparing antigen retrieval solutions and for wash 
buffers. 
10. Pressure cooker for antigen retrieval. 
11. Kit for performing immunohistochemistry which includes primary 
antibody (CD3, CD5, CD10, CD20) and universal kit. Microscope 
used for interpretation and grading of IHC. 
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METHODOLOGY 
 
The method of performing immunohistochemistry over the paraffin 
tissue microarray includes the following steps. 
1. Designing the layout for TMA construction. 
2. Collection of the donor blocks. 
3. Preparation of the recipient paraffin blocks. 
4. Immunohistochemistry and analysis. 
Designing the lay out 
Before constructing the array proper, the layout of the tissue 
microarray defining the geometric position of each tissue core in the 
recipient block was made. The grid was constructed in such a way that there 
were minimum of two cores from each case and maximum of three cores on 
the recipient blocks except for two cases which had single representative 
core. All the cores from each case were placed in the same block in different 
positions. The grid was constructed in such a way that there were blank 
cores in between the cores from the cases which helped in determining the 
position of the cases on the immunohistochemistry performed slides. 
Collection of the donor blocks 
The hematoxylin and eosin stained sections which were prepared 
from formalin fixed paraffin embedded blocks of all the cases of Non-
Hodgkin lymphoma in the Department of pathology during the study period 
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were retrieved. The corresponding formalin fixed paraffin embedded tissues 
were also obtained which constituted the donor block. Then the hematoxylin 
and eosin stained slides which contained full sections were examined and 
the area of interest was marked by using black glass marking pen. The area 
of interest is nothing but the area of tumor containing well preserved and 
well stained malignant cells. Then these marked areas on the slides were 
matched with the donor blocks and the corresponding areas over the donor 
blocks were also marked with the help of black glass marking pen. This area 
was used as the site for obtaining cores for the recipient blocks.  
Preparation of the recipient paraffin blocks 
The empty paraffin recipient blocks with minimum size of   25mm x 
25mm were first prepared by freshly poured molten wax in the metal 
moulds. Then it was allowed to cool. Later using 16gauge needle, paraffin 
wax cylinders of 2mm diameter were punched from the recipient blocks. 
Each block contained 3x3 cylinder matrix at a distance less than 2mm. 
Seven such blocks were prepared.  
Then using 14gauge bone marrow aspiration needle, tissue cylinders 
were obtained from the area of interest which were previously marked over 
the donor blocks, after which it was injected into the recipient blocks into 
the corresponding empty cylinders with the help of  predesigned layouts so 
that each recipient blocks contained three cases. After the recipient block 
was embedded with the tissue cores, the block was incubated at 40
0
c for 15 
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minutes and then it was allowed to cool for few minutes at room 
temperature and then the array was chilled on the ice for few minutes. 
Finally the 5microns sections were taken over the surface of the APES (3-
aminopropyltriethoxysilane) coated slides using a microtome. 
IMMUNOHISTOCHEMISTRY    
Section cutting 
Sections were taken at 5microns thickness after tissue microarray 
construction along with a control section on the surface of the APES (3-
aminopropyltriethoxysilane) coated slides. This was followed by incubation 
of slides at 58-60
0
c for one hour. 
Antigen retrieval solution 
We used two antigen retrieval solution and a wash buffer as 
prescribed by the manufacturer (DAKO). 
1. Citrate buffer at a PH of 6.2 for CD3, CD5, CD10. 
2. Tris EDTA at a PH  of 9 for CD20. 
3. Tris wash buffer at PH  of  7.6 for both. 
Antigen retrieval 
Many methods have been used for antigen retrieval which includes 
Microwave method, and water bath, autoclave, proteolytic enzyme and 
pressure cooker method. In our institution we followed antigen retrieval by 
using pressure cooker as it produces even heating with lesser disadvantages 
as compared to other methods.  
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Procedure for immunohistochemistry as given by manufacturer 
1. Section cutting and incubation is followed by Xylene wash (3 
changes) for 10minutes each. 
2. Rehydrated in graded alchohol containing 100%, 80%, 70% for five 
minutes each. 
3. Rinsed in distilled water for 2minutes. 
4. Antigen retrieval. 
5. Cooling for 15minutes. 
6. Washed in TBS wash buffer- 3changes 5minutes each. 
7. Treated with peroxide block for 10minutes. 
8. Washed in TBS wash buffer- 3changes 10minutes each. 
9. Kept in protein block for 10minutes. 
10. Application of primary antibody (CD3/CD5/CD10/CD20) – 1 Hour. 
11. Washed in TBS wash buffer- 3changes 10minutes each. 
12. Amplifier application for 15minutes. 
13. Washed in TBS wash buffer- 3changes 10minutes each. 
14. Application of secondary antibody (HRP POLYMERASE). 
15. Washed in TBS wash buffer- 3changes 10minutes each. 
16. Application of Diamino-benzidine tetrachloride(DAB) chromogen. 
17. Washed in distilled water – 2 changes. 
18. Counterstaining with Mayer‘s Hematoxylin – 1dip/30seconds to 
impart background staining. 
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19. Wash in running tap water. 
20. Place in xylene – 2 changes 5 minutes each. 
21. Dehydrate in 100% alcohol – 5minutes. 
22. Mount the section with Dextrene phthalate xylene 
23. Observation and grading under light microscope. 
Grading of IHC stained sections 
After immunohistochemistry was done, the slides were examined 
under all the magnification with the help of light microscopy and grading is 
done. This is done by following the method as opted by Afaf Abdel- Aziz, 
Abdel-Ghafar
(135)
 in his study on ―Immunophenotyping of chronic B-cell 
neoplasms‖. First the tumour cells are observed for positive 
membrane/cytoplasmic staining pattern after which it is graded based upon 
the percentage of tumour cells which shows positive expression of antibody 
used as follows, 
No Reaction: 0. 
Less than 5% of the tumour cells showing positive 
membranous/cytoplasmic expression: 1+. 
5-9% of the tumour cells showing positive membranous/cytoplasmic 
expression: 2+. 
10-20% of the tumour cells showing positive   
membranous/cytoplasmic expression: 3+.                                                           
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More than 20% of the tumour cells showing positive 
membranous/cytoplasmic expression: 4+. 
After IHC grading, the cases are re-classified as per WHO 
classification of lymphoid neoplasms (International agency for research on 
cancer, Lyon, 2008)
(78) 
and results are tabulated for analysis.   
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OBSERVATION AND RESULTS 
TABLE 1: Comparison of Histopathological and immunohistochemical 
diagnosis 
 
S 
no 
 
Histopathology 
no 
 
Age 
 
Sex 
 
Site 
Histopathological 
diagnosis 
Diagnosis after  
immunohistochemistry 
(based on who 
classification-2008) 
1 1567/11 
 
65 F Femoral Large cell 
anaplastic 
lymphoma 
Diffuse large b cell 
lymphoma 
 
2 1593/11 
 
62 F Axilla Diffuse non 
hodgkin 
lymphoma 
Cll/sll   /  mantle cell 
lymphoma 
 
3 1813/11 
 
65 F Cervical Diffuse small & 
large cell 
lymphoma 
Diffuse large b cell 
lymphoma 
 
4 2857/11 
 
15 M Cervical Follicular 
lymphoma 
Nodal marginal zone 
lymphoma 
5 2860/11 
 
60 M Cervical Diffuse small cell 
lymphoma 
Cll/sll  /   mantle cell 
lymphoma 
6 2426/11 
 
78 M Cervical Non hodgkin 
lymphoma 
Cll/sll  /   mantle cell 
lymphoma 
7 2551/12 
 
60 M Cervical Diffuse mixed cell 
type of nhl 
Diffuse large b cell 
lymphoma 
8 2072/12 
 
11 M Cervical Reactive follicular 
hyperplasia with 
progressive 
transformation of 
germinal centre. 
Progressive 
transformation of 
germinal centre 
 
9 3143/12 
 
11 M Cervical Non hodgkin 
lymphoma with 
rdd changes 
Cll/sll   /   mantle cell 
lymphoma 
 
10 2444/13 
 
65 M Cervical Non hodgkin 
lymphoma, diffuse 
type 
Diffuse large b cell 
lymphoma 
 
11 1883/13 
 
53 F Mesentric Non Hodgkin 
lymphoma,mixed 
type 
Diffuse large b cell 
lymphoma 
 
12 2607/13 
 
45 F Mesentric Mantle cell   
lymphoma 
Mantle cell lymphoma 
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13 0026/11 
 
55 M Axilla Large cell 
anaplastic 
lymphoma 
Diffuse large b cell 
lymphoma 
 
14 2928/13 
 
60 F Cervical Non hodgkin 
lymphoma 
Cll/sll   /   mantle cell 
lymphoma 
15 1438/13 
 
65 F Cervical Nhl, follicular and 
mixed cell type 
Diffuse large b cell 
lymphoma 
 
16 1104/14 
 
65 M Axilla, 
inguinal 
Angioimmunoblas
tic 
lymphadenopathy 
T cell lymphoma 
 
17 980/14 
 
53 F Axilla Non hodgkin 
lymphoma 
Cll/sll   /    mantle cell 
lymphoma 
 
18 0095/14 
 
44 M Omentum Small cell 
carcinoma/lympho
ma 
Mantle cell lymphoma 
 
19 1998/14 
 
60 M Inguinal Non hodgkin 
lymphoma 
Diffuse large b cell 
lymphoma 
20 1428/14 
 
75 M Axilla Lymphoproliferati
ve disorder 
Not possible 
 
21 768/14 
 
60 M Cervical Non hodgkin 
lymphoma 
Diffuse large b-cell 
lymphoma - nos 
 
All the cases diagnosed histopathologically as Non Hodgkin 
lymphoma are confirmed to be of the same class by immunohistochemistry 
except for one case of lymphoproliferative disorder in which the diagnosis 
was not possible. So the concordance rate of immunohistochemical analysis 
with hisopathological examination was 95%. 
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TABLE 2: DISTRIBUTION OF CASES 
                            Case Number of cases Percentage of 
cases 
Total number of cases 21 100% 
Histopathologically diagnosed 
NHL 
20 95.24% 
Immunohistochemically proven 
NHL 
19 90.48% 
NHL of B-cell type 18 85.71% 
NHL of T-cell type 1 4.76% 
Progressive transformation of 
germinal centre(PTGC) 
1 4.76% 
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                                                    CHART-1 
 
 
 
 
 
Out of the 19 cases that were classified by immunohistochemistry, B 
cell lymphoma constituted 18 cases and there was a single case of T cell 
lymphoma. Thus B cell lymphoma type formed the majority of Non 
Hodgkin lymphoma. 
 
 
 
 
93%
94%
95%
96%
97%
98%
99%
100%
21 20 19 18 1 1 
100% 95.24% 90.48% 85.71% 4.76% 4.76% 
Percentage of cases
  Number of cases
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TABLE 3: CLASSIFICATION OF B-CELL LYMPHOMA AFTER 
 IMMUNOHISTOCHEMICAL ANALYSIS 
 
B-CELL NHL NUMBER OF CASES PERCENTAGE 
Diffuse large B-cell 
lymphoma 
9 50% 
CLL/SLL  /  Mantle 
cell Lymphoma 
6 33.33% 
Mantle cell lymphoma 2 11.11% 
Nodal marginal zone 
lymphoma 
1 5.5% 
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                                             CHART-2 
 
 
 
 
Diffuse large B-cell lymphomas are the most common type of B-cell 
lymphomas encountered. CLL/SLL  /  Mantle cell lymphoma stand next to 
DLBCL. 
 
 
 
 
 
 
 
92%
93%
94%
95%
96%
97%
98%
99%
100%
Diffuse
large B-cell
lymphoma
CLL/SLL  /
Mantle cell
Lymphoma
Mantle cell
lymphoma
Nodal
marginal
zone
lymphoma
9 
6 
2 
1 
50% 33.33% 11.11% 5.50% 
Series2
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89 
 
TABLE4: PATTERN AND GRADE OF STAINING IN NON 
HODGKIN   LYMPHOMA 
Histopathology 
no 
Diagnosis after  
immunohistochemistry 
 
CD3 
 
CD20 
 
CD5 
 
CD10 
1567/11 
 
DIFFUSE LARGE B 
CELL LYMPHOMA 
0 Diffuse 
4+ 
Diffuse 
2+ 
Diffuse 
1+ 
1593/11 
 
CLL/SLL  / MANTLE 
CELL LYMPHOMA 
0 Diffuse 
4+ 
Diffuse 
2+ 
0 
1813/11 
 
DIFFUSE LARGE B 
CELL LYMPHOMA 
0 Diffuse 
4+ 
0 Diffuse 
1+ 
2857/11 
 
NODAL MARGINAL 
ZONE LYMPHOMA 
Focal-
interfollicular 
1+ 
Diffuse 
4+ 
Diffuse 
2+ 
0 
2860/11 
 
CLL/SLL / MANTLE 
CELL LYMPHOMA 
Focal 
follicular 2+ 
Diffuse 
4+ 
Diffuse 
3+ 
0 
2426/11 
 
CLL/SLL  / MANTLE 
CELL LYMPHOMA 
0 Diffuse 
4+ 
Diffuse 
2+ 
0 
2551/12 
 
DIFFUSE LARGE B 
CELL LYMPHOMA 
Focal 
2+ 
Diffuse 
3+ 
Diffuse 
3+ 
Diffuse 
1+ 
2072/12 
 
PROGRESSIVE 
TRANSFORMATION 
OF GERMINAL 
CENTRE 
Focal-
interfollicular 
2+ 
Follicular 
3+ 
Focal-
follicular 
3+ 
0 
3143/12 
 
CLL/SLL / MANTLE 
CELL LYMPHOMA 
0 Diffuse 
3+ 
Diffuse 
3+ 
0 
2444/13 
 
DIFFUSE LARGE B 
CELL LYMPHOMA 
Focal 
1+ 
Diffuse 
3+ 
0 Diffuse 
1+ 
1883/13 
 
DIFFUSE LARGE B 
CELL LYMPHOMA 
0 Diffuse 
3+ 
0 Diffuse 
1+ 
2607/13 
 
MANTLE CELL 
LYMPHOMA 
Focal- 
follicular1+ 
Diffuse 
3+ 
Diffuse 
2+ 
0 
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All of the 9 cases of diffuse large B cell lymphoma showed diffuse 
pattern of staining with CD 20 and CD10, 5 cases showed diffuse pattern of 
staining for CD5 and 3 cases showed focal non specific staining for CD3. 
Out of the 6 cases of CLL/SLL / Mantle cell lymphoma, all of them showed 
diffuse pattern of staining for CD20 and CD5 and one case showed focal 
0026/11 
 
DIFFUSE LARGE B 
CELL LYMPHOMA 
0 Diffuse 
3+ 
Diffuse 
1+ 
Diffuse 
2+ 
2928/13 
 
CLL/SLL / MANTLE 
CELL LYMPHOMA 
0 Diffuse 
3+ 
Diffuse 
1+ 
0 
1438/13 
 
DIFFUSE LARGE B 
CELL LYMPHOMA 
Focal 
2+ 
Diffuse 
3+ 
Diffuse 
3+ 
Diffuse 
1+ 
1104/14 
 
T CELL LYMPHOMA 
 
Diffuse 
2+ 
0 Focal 
2+ 
0 
980/14 
 
CLL/SLL / MANTLE 
CELL LYMPHOMA 
 
0 Diffuse 
1+ 
Diffuse 
2+ 
0 
0095/14 
 
MANTLE CELL 
LYMPHOMA 
 
0 Diffuse 
1+ 
Focal-
follicular 
3+ 
0 
1998/14 
 
DIFFUSE LARGE B 
CELL LYMPHOMA 
 
0 Diffuse 
1+ 
Diffuse 
1+ 
Diffuse 
2+ 
1428/14 
 
NOT POSSIBLE 
 
Loss loss Diffuse 
1+ 
Loss 
768/14 
 
DIFFUSE LARGE B-
CELL LYMPHOMA - 
NOS 
0 Diffuse 
2+ 
Loss Loss 
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staining in the interfollicular area with CD3. Out of the 2 cases of mantle 
cell lymphoma, one case showed diffuse staining of CD20 and CD5 with 
focal staining in the follicular area with CD3 while the other showed diffuse 
staining with CD20 and focal follicular staining with CD 5. The single case 
of nodal marginal zone lymphoma showed diffuse staining pattern with 
CD20 and CD5 and interfollicular area was positively stained with CD3.  
The one case that was diagnosed as T cell lymphoma showed diffuse grade 
2+ positivity for CD3 and focal grade 2+positivity for CD5 while CD20 was 
negative.  
 Out of the 9 cases of diffuse large B cell lymphoma, 5 of them 
showed grade 4+ membrane positivity, 2 of them showed grade 3+  
membrane positivity and one case showed grade 1+ membrane positivity 
with CD20. As far as CD10 was concerned in diffuse large B cell 
lymphoma cases, 2 of them showed grade2+ membrane positivity and the 
rest had grade 1+  membrane positivity. Out of the 6 cases of CLL/SLL / 
Mantle cell lymphoma, 3 cases showed grade 4+ membrane positivity, 2 
were grade 3+ membrane positive and rest showed grade 1+ membrane 
positivity with CD20. As far as CD5 was concerned in CLL/SLL / Mantle 
cell lymphoma cases, 2 cases showed grade 3+ and 3 of them showed 
grade2+ membrane positivity while one case showed grade 1+  membrane 
positivity. Out of the single case of nodal marginal zone lymphoma there 
was grade 2+ positivity for CD5, grade 4+  positivity for CD20 and grade 
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1+ positivity for CD3. Mantle cell lymphoma cases, one had grade 3+ 
positivity for CD20 and grade 2+ positivity for CD5 while the other had 
grade1+ for CD 20 and 3+ for CD5. 
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TABLE5: QUANTIFICATION OF IHC REAGENTS USED IN 
CONVENTIONAL VS TMA SECTIONS 
 
The conventional immunohistochemistry using full section consumes 
0.8 IU of the chemical reagents whereas only one sixth of the reagent is 
consumed by tissue microarray. 
 
 
IMMUNOHISTOCHEMICAL 
REAGENT 
 
TMA 
 
CONVENTIONAL 
 
CONSUMPTION 
RATIO 
 
Primary antibody 
 
.13 
IU 
 
.8 IU 
 
1:6 
 
Secondary antibody 
 
.13 
IU 
 
.8 IU 
 
1:6 
 
Chromogen 
 
.13 
IU 
 
.8 IU 
 
1:6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Colour Plates 
 Fig.Ia. A case of diffuse large B-cell lymphoma showing diffuse positive 
expression for CD 20 (IHC, x100). 
 
 
Fig.Ib. A case of diffuse large B-cell lymphoma showing positive 
membrane expression for CD20  (IHC, x400). 
 Fig.IIa. Diffuse CD5 expression in a case of CLL/SLL (IHC, x100). 
 
 
 
Fig.IIb. Section showing positive cytoplasmic membrane expression for CD5          
(IHC, x 400). 
 Fig.IIIa. Positive expression for CD5 in a case of mantle cell lymphoma 
     (IHC, x40). 
 
 
Fig.IIIb. A case of mantle cell lymphoma showing focal follicular expression 
for CD5 (IHC, x100). 
 
 
  
 
 
 
 
 
 
Fig.IIIC. Positive membrane expression for CD5 in the follicles in a case of 
mantle cell lymphoma (IHC, x400). 
 
 
 
 
 
 
 
 
 Fig.IVa. A case of T-cell lymphoma showing positive expression for CD3 
    (IHC, x100). 
 
 
Fig.IVb. CD3, showing positive membrane expression in a case of T-cell 
lymphoma (IHC, x400). 
Fig.V. Materials used in the construction of tissue 
microarray 
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DISCUSSION 
 
The application of tissue microarray for the use of 
immunohistochemical diagnosis and classification of lymphoma has gained 
importance in the field of medical research for evaluation of prognosis and 
treatment modalities. 
Lynette K Tumwine
(116), in his study ―Immunohistochemical and 
other prognostic factors in B cell NHL‖, at Kampala, Uganda used TMA for 
IHC analysis of NHL and studied prognostic factors in B cell lymphoma. 
According to Christian Hans et al
(119)
 in his study immunostaining of 
DLBCL using TMA correlated with 71% cases of the GCB group and 88% 
cases the non-GCB group when compared with gene profiling using cDNA.              
The present study included 21 cases of Histomorphologically 
diagnosed Non- Hodgkin lymphomas. All of the cases were subjected to 
immunohistochemistry with the help of Tissue microarray, to confirm the 
histopathological diagnosis and to classify NHL into B-cell type and T-cell 
type. Subtyping of B-cell Lymphoma has also been done with the help of 
available immunohistochemical markers.  After immunohistochemical 
study, out of 21 cases 1 case was confirmed as progressive transformation of 
germinal centre, and in one case opinion was not possible due to tissue loss. 
Hence out of 21 cases studied 19 cases were taken into the analysis. 
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Among 19 cases analysed 18 were Non-Hodgkin lymphoma of B-cell 
type which constituted for 94.73%. One case of T-cell lymphoma was 
observed which accounted for 5.27%.According to Naresh KN 2000
(178)
, B 
cell lymphoma formed 79.1% of NHL, 72% according to Kalyan K et al, 
2006
(179)
, 86% according to Mushtaq S et al
(180)
, 2008, 96% according to 
Padhi S et al, 2012
(181)
 and 54% according to Rao et al, 2013
(1)
. This 
correlates with the results of the current study. According to K.E.Hunt and 
Reichard, 2008 
(182)
, diffuse B cell lymphomas are the most frequently 
occurring B cell Non Hodgkin lymphoma, worldwide. In two studies 
reported from Mumbai (India) in the year 2000
(178) 
and 2011
(183)
, DLBCL 
was found to be 34% and 42% respectively. Roy et al, Kalyan et al and 
Padhi et al found that DLBCL formed 29.3%, 26% and 69% of B cell 
lymphomas, respectively. In the current study diffuse large B-cell 
lymphoma formed the bulk. There were 9cases of DLBCL which accounted 
for 50%. This result was similar to the above mentioned studies. 
          According to Jaffe ES
(184)
, mantle cell comprises about 2-10% of all 
Non-Hodgkin lymphoma. Roy et al
(185)
, through his study documented that 
mantle cell lymphoma ,marginal zone lymphoma and CLL/SLL constituted 
for 4%, 2.7% and 13% respectively. Naresh et al in his study found that 
3.4% of the cases were of mantle cell type, 8.2% of the cases were marginal 
zone lymphomas and 5.7% of the cases were CLL/SLL. In the current study, 
cases which showed small cell morphology along with CD20 and CD5 
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positivity were categorised as CLL/SLL / Mantle cell lymphoma but further 
classification was not done due to non availability of cyclinD1. This 
constituted 33.33%. Two cases of mantle cell lymphoma were diagnosed, 
correlating with cell morphology, immunohistochemistry and one case was 
associated with lymphomatous polyposis in the ileum. Mantle cell 
lymphoma accounted for 11.11% and nodal marginal zone lymphoma 
accounted for 5.5% of cases. 
         According to Picker LJ
(122)
, all the cases of diffuse large B-cell 
lymphoma expresses CD20 and Fang JM
(124)
 et al through his study found 
that 20-30% of the cases of DLBCL are positive for CD10. Vasef MA 
(130)
 
found that CD5 is nearly negative in all the cases of DLBCL and according 
to Dogan A
(186)
 CD10 expression is absent in half the cases of diffuse large 
B-cell lymphomas.  In this study, cases with predominantly large cell and 
mixed cell histomorphology with variable positive membranous expression 
for CD20 and CD10 were diagnosed to be diffuse large B cell lymphoma. 9 
such cases diagnosed, 5 of them showed grade 4+ diffuse positivity with 
CD20 and 6 of them showed grade1+ diffuse positivity with CD10. The 
CD20 expression in this study was similar to the above studies but they 
differed in CD10 expression. 
Sumeet Gujaral
(187)
 in his study of 93 cases of mantle cell lymphoma 
found that 68 cases showed positive expression for CD20 and 61 cases 
showed positivity for CD5.Arun Roy
(188)
 in his study documented that all 
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the 13 cases he included in his study showed positive expression for CD5 
and CD20. Cheson BD
(189)
 and Matutes E
(190)
 through their study 
documented that the cells of CLL/SLL shows positive expression for CD20 
and CD5 with negative expression for CD10. The cases with predominantly 
small cell histomorphology with variable positive membranous expression 
for CD20 and CD5 were categorised as CLL/SLL / Mantle cell lymphoma. 
6 such cases were diagnosed.  
One case with small cell morphology with 3+ membrane expression 
for CD 20, 2+ membrane expression for CD5 and 1+ membrane expression 
for CD3 along with lymphomatous polyposis of ileum was diagnosed as 
mantle cell lymphoma. Another case with diffuse grade1+ CD20 positivity 
with follicular grade 3+ positivity for CD5 was diagnosed as mantle cell 
lymphoma. The results obtained in this study was similar to the above 
mentioned studies. 
Watson et al
(191)
, Kurin PJ
(192)
 and Campo E
(193)
 found that most cases 
of nodal marginal zone lymphomas show positive expression for CD20 with 
negative expression of CD3, CD5, CD10. In the current study, the case 
which showed monotonous lymphoid cell proliferation with marginal zone 
expansion histomorphologically with positive membrane expression for 
CD20, CD5 and CD3 was diagnosed as nodal marginal zone lymphoma. 
The result obtained differed from the above studies. 
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NHL affects all the age group, commonly involving the elderly 
individual. The median age of incidence of NHL in Asian countries is 
significantly lower compared to the population based registration in Western 
countries. On the basis of data collected by Smith et al 
(194)
, the median age 
of the patients was reported as 68 years by the Hematological Malignancy 
Research Network. However, the median age of the patient is 54 years in 
Asia, 54 years in Taiwan (Lee,Tan, Feng, 2005) 
(195)
, 52 years in Korea (Y-
H Ko et al, 1998)
(196)
 54.5 years in Japan (Aozasa, et al, 1985) 
(197)
, 55 years 
in Iran (Mozaheb, Farzad, Aledavod, 2011)
(198)
.  In the present study, 
maximum cases of NHL were over 40 years of age which constitutes for 
about 47.36% of total NHL cases and 50% of B-cell lymphoma. There were 
about 15 cases of NHL over 49 years among 19 cases of total NHL and 
14cases of NHL over 49 years among 19 cases of B-cell NHL which 
accounted for 78.94% and 77.77%, respectively.  
According to Manzoor Ahmed, Amir Hussain Kahn, Sami Saeed
 (199)
, 
78.78% of cases of NHL presented with lymph node enlargement. Among 
these, 40.5% had generalised lymphadenopathy whereas 24% of patients 
had cervical lymph node enlargement. Sudiptachakravarthi, 
SupriyaSarkar
(200)
 in their study documented that peripheral 
lymphadenopathy was noted in 94.7% of cases of NHL with associated 
symptoms of anemia in 60.5% of the cases.  The size of the lymph node also 
plays an important role in the diagnosis of lymphoma. A diameter larger 
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than 3cm, firm consistency, white colored nodular cut surface are the 
features suggestive of neoplastic transformation of the node. 
In current study the patients of NHL presented with lymph node 
enlargement with one of the case showing additional lesion in the ileum and 
other case in the skin. Maximum number of patients showed cervical group 
of enlarged lymph nodes which constituted for 57.89% (11cases). The 
maximum size of enlarged node was found to be 6cm with minimum size of 
0.3cm.  
According to Mucci NR et al 
(201)
, Schrami et al
(202)
 and Richter J et 
al
(203)
 tissue loss may be significant using tissue micro array with rate of 
tissue damage ranging from 15-33%. Hager M et al 
(34)
 in his study on renal 
cell carcinoma using tissue micro array observed tissue loss due to technical 
problems which accounted for 23%. In the present study tissue loss was 
found among two cases during the procedure which accounts for 10%. This 
may be attributed to small core depth, improper embedding, faulty section 
cutting, and improper antigen retrieval technique. These can be overcome 
by following standard protocols and obtaining more number of tissue cores 
especially triplicate cores from the donor block. 
The use of chemicals for performing IHC is critical using tissue micro 
array. We used insulin syringe for dispersal of primary antibody, secondary 
antibody and DAB chromogen. To analyse single conventional tissue 
section immunohistochemically, minimum of two drops (0.8IU) of chemical 
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reagents which includes primary antibody, secondary antibody and DAB 
chromogen are required. 1 ml insulin syringe can hold 40IU of the reagent 
which equals 100 drops. Hence, a single tissue section when used 
conventionally consumes 0.8IU of the reagent whereas in TMA, the same 
quantity has been used to analyze 6 cores taken from three different cases. 
So TMA, apart from having the advantage of parallel analysis of multiple 
sections also decreases the time taken for the IHC procedure and the amount 
of chemical reagents used. Furthermore, the use of immunohistochemical 
analysis in NHL by tissue microarray is helpful in comparative analysis of 
the tumor, sub-classification which is essential for determining treatment, 
prognosis and standardisation of the chemical reagents.  
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SUMMARY AND CONCLUSION 
 
This study was conducted in Department of pathology, Tirunelveli 
medical college in which tissue micro array was prepared from lymph nodes 
of 21 cases among which 20 were diagnosed as Non-Hodgkin lymphoma by 
histomorphology. All the cases were subjected for immunohistochemical 
analysis using CD3, CD5, CD10 and CD20 from which 19 cases were taken 
for analysis because of tissue loss in one case. Among 19, 18 cases were 
Non-Hodgkin lymphoma of B-cell type but for a case of T-cell lymphoma. 
There were nine cases of diffuse large B-cell lymphoma and six cases of 
small cell lymphoma/mantle cell lymphoma. Mantle cell lymphoma 
constituted for two cases and nodal marginal zone lymphoma for a single 
case.  
Most of the Non-Hodgkin lymphomas have aggressive clinical course 
and hence need to be diagnosed and categorised earlier using 
immunophenotyping. WHO classification of lymphoid neoplasms (2008), 
classifies lymphoma based on immunophenotypic features apart from 
histomorphological and molecular genetics. Hence, basic panel of markers 
were used on the tissue microarray for the classification of Non Hodgkin 
lymphoma cases diagnosed based on histomorphological features. 
The process of immunohistochemistry using conventional tissue 
section consumes more reagents, also require control and standardization for 
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each batch when compared to tissue microarray. By taking representative 
cores from different cases and performing IHC on them on a single slide not 
only proved to be economical but also aided in the standardisation of the 
reagents and procedure. Immunohistochemical analysis with a panel of 
markers using tissue microarray greatly reduces time and quantity of 
reagents. Application of a basic required panel of markers for 
immunophenotyping of the Non Hodgkin Lymphoma aid in the sub-
classification as per WHO guidelines and could modify the therapeutic 
modalities, thereby prognosis. In this scenario, using a basic panel of 
markers for immunohistochemistry on tissue microarray saves time, cost 
and aids in precise tissue diagnosis. 
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Annexure I – Master Chart 
SN IP no HPE no AGE SEX SPECIMEN     SITE
SIZE 
(largest 
dimension 
in cm)
HPE 
DIAGNOSIS
No OF 
CORES
TMA 
BLOCK NO
TMA CORE 
POSITION
             FINAL DIAGNOSIS
CD3 CD20 CD5 CD10 CD3 CD20 CD5 CD10
1 25758 1567/11 65 F
LYMPH 
NODE
FEMORAL 6
LARGE 
CELL 
ANAPLASTI
C 
LYMPHOM
A
3 BLOCK1
1A1,1A2,1
A3
NEGATIVE
      
DIFFUSE
DIFFUSE DIFFUSE 0        4+      2+      1+
DIFFUSE LARGE B CELL 
LYMPHOMA
2 29234 1593/11 62 F
LYMPH 
NODE
AXILLA 4
DIFFUSE 
NHL
2 BLOCK1 1B1,1B3 NEGATIVE DIFFUSE DIFFUSE NEGATIVE 0        4+      2+ 0
CLL/SLL OR MANTLE CELL 
LYMPHOMA
3 34538 1813/11 65 F
LYMPH 
NODE
CERVICAL 1
DIFFUSE 
SMALL & 
LARGE 
CELL 
LYMPHOM
A
2 BLOCK1 1C1,1C2 NEGATIVE DIFFUSE NEGATIVE DIFFUSE 0        4+ 0      1+
DIFFUSE LARGE B CELL 
LYMPHOMA
4 55544 2857/11 15 M
LYMPH 
NODE
CERVICAL 2
FOLLICULA
R 
LYMPHOM
A
3 BLOCK2
2D1,2D2,2
D3
FOCAL-
INTERFOLL
ICULAR
DIFFUSE DIFFUSE NEGATIVE     1+        4+      2+ 0
NODAL MARGINAL ZONE 
LYMPHOMA
5 54433 2860/11 60 M
LYMPH 
NODE
CERVICAL 2
DIFFUSE 
SMALL 
CELL 
LYMPHOM
A
2 BLOCK2 2E1,2E2
FOCAL- 
FOLLICULA
R
DIFFUSE DIFFUSE NEGATIVE     2+       4+      3+ 0
CLL/SLL OR MANTLE CELL 
LYMPHOMA
6 43617 2426/11 78 M
LYMPH 
NODE
CERVICAL 1.5 NHL 2 BLOCK2 2F1,2F2 NEGATIVE DIFFUSE DIFFUSE NEGATIVE 0       4+      2+ 0
CLL/SLL OR MANTLE CELL 
LYMPHOMA
7 51884 2551/12 60 M
LYMPH 
NODE
CERVICAL 2
DIFFUSE 
MIXED 
CELL TYPE 
OF NHL
3 BLOCK3
3G1,3G2,3
G3
FOCAL-
INTERFOLL
ICULAR
DIFFUSE DIFFUSE DIFFUSE     2+      3+     3+      1+
DIFFUSE LARGE B CELL 
LYMPHOMA
8 45082 2072/12 11 M
LYMPH 
NODE
CERVICAL 1.5
RFH WITH 
PTGC
2 BLOCK3 3H1,3H3
FOCAL-
INTERFOLL
ICULAR
FOLLICULA
R
FOCAL-
FOLLICULA
R
NEGATIVE     2+      3+     3+ 0
PROGRESSIVE 
TRANSFORMATION OF 
GERMINAL CENTRE
9 64414 3143/12 11 M
LYMPH 
NODE
CERVICAL 3
NHL WITH 
RDD 
CHANGES
3 BLOCK3 3I2,3I3 NEGATIVE DIFFUSE DIFFUSE NEGATIVE 0      3+     3+ 0
CLL/SLL OR MANTLE CELL 
LYMPHOMA
10 52954 2444/13 65 M
LYMPH 
NODE
CERVICAL 1
NHL,DIFFU
SE TYPE
3 BLOCK4 4J1,4J2,4J3 FOCAL DIFFUSE NEGATIVE DIFFUSE      1+      3+ 0       1+
DIFFUSE LARGE B CELL 
LYMPHOMA
11 45789 1883/13 53 F
LYMPH 
NODE
MESENTRI
C
0.5
NHL, 
MIXED 
TYPE
1 BLOCK4 4K2 NEGATIVE DIFFUSE NEGATIVE DIFFUSE 0      3+ 0      1+
DIFFUSE LARGE B CELL 
LYMPHOMA
12 56822 2607/13 45 F
LYMPH 
NODE
MESENTRI
C
0.3
MANTLE 
CELL 
LYMPHOM
A
2 BLOCK4 4L1,4L3
FOCAL-
FOLLICULA
R
DIFFUSE DIFFUSE NEGATIVE     1+      3+     2+ 0 MANTLE CELL LYMPHOMA
13 58077 0026/11 55 M
LYMPH 
NODE
AXILLA 1.5
LARGE 
CELL 
ANAPLASTI
C 
LYMPHOM
A
3 BLOCK5
5M1,5M2,
5M3
NEGATIVE DIFFUSE DIFFUSE DIFFUSE 0      3+      1+      2+
DIFFUSE LARGE B CELL 
LYMPHOMA
14 160424 2928/13 60 F
LYMPH 
NODE
CERVICAL 1.5 NHL 2 BLOCK5 5N1,5N3 NEGATIVE DIFFUSE DIFFUSE NEGATIVE 0      3+      1+ 0
CLL/SLL OR MANTLE CELL 
LYMPHOMA
IHC GRADINGPATTERN OF STAINING IN IHC
MASTER CHART
15 39870 1438/13 65 F
LYMPH 
NODE
CERVICAL 1
NHL, 
FOLLICULA
R TYPE
3 BLOCK5 5O1,5O2 FOCAL DIFFUSE DIFFUSE DIFFUSE      2+      3+      3+      1+
DIFFUSE LARGE B CELL 
LYMPHOMA
16 18724 1104/14 65 M
LYMPH 
NODE
AXILLA, 
INGUINAL
3
ANGIOIM
MUNOBLA
STIC 
LYMPHADE
NOPATHY
3 BLOCK6
6P1,6P2,6P
3
DIFFUSE NEGATIVE FOCAL NEGATIVE     2+ 0      2+ 0 T CELL LYMPHOMA
17 33143 980/14 53 F
LYMPH 
NODE
AXILLA 0.7 NHL 2 BLOCK6 6Q1,6Q2 NEGATIVE DIFFUSE DIFFUSE NEGATIVE 0       1+      2+ 0
CLL/SLL OR MANTLE CELL 
LYMPHOMA
18 13933 0095/14 44 M
LYMPH 
NODE
OMENTU
M
1
SMALL 
CELL 
CARCINOM
A/LYMPHO
MA
2 BLOCK6 6R1,6R3 NEGATIVE DIFFUSE
FOCAL-
FOLLICULA
R
NEGATIVE 0       1+      3+ 0 MANTLE CELL LYMPHOMA
19 35334 1998/14 60 M
LYMPH 
NODE
INGUINAL 2 NHL 2 BLOCK7 7S2,7S3 NEGATIVE DIFFUSE DIFFUSE DIFFUSE 0       1+      1+      2+
DIFFUSE LARGE B CELL 
LYMPHOMA
20 22556 1428/14 75 M
LYMPH 
NODE
AXILLA 3
LYMPHOP
ROLIFERAT
IVE 
DISORDER
2 BLOCK7 7T1,7T3 LOSS LOSS DIFFUSE LOSS LOSS LOSS      1+ LOSS NOT POSSIBLE
21 14458 768/14 60 M
LYMPH 
NODE
CERVICAL 3 NHL 1 BLOCK7 7U1 NEGATIVE DIFFUSE LOSS LOSS 0      2+ LOSS LOSS
DIFFUSE LARGE B-CELL 
LYMPHOMA-NOS
                              KEY TO THE MASTER CHART 
 
CD  –  Cluster of Differentiation.  
F  –  Female.  
HPE.NO  –  Histopathological Examination Number.  
IHC  –  Immunohistochemistry.  
IP.NO  –  In patient number.  
M  –  Male.  
NHL  –  Non Hodgkin Lymphoma.  
PTGC  – Progressive Transformation of Germinal Centre. 
RFH –  Reactive Follicular Hyperplasia. 
RDD  –  Rosai Dorfman Disease. 
S.N –  Serial Number. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Annexure II – TMA layout 
TMA LAYOUT
1567/11 BLOCK 1 1 2 3
1593/11 A 1567/11 1567/11 1567/11
1813/11 B 1593/11 BLANK 1593/11
2857/11 C 1813/11 1813/11 BLANK
2860/11  BLOCK2
2426/11 D 2857/11 2857/11 2857/11
2551/12 E 2860/11 2860/11 BLANK
2072/12 F 2426/11 2426/11 BLANK
3143/12  BLOCK3
2444/13 G 2551/12 2551/12 2551/12
1883/13 H 2072/12 BLANK 2072/12
2607/13 I BLANK 3143/12 3143/12
0026/11   BLOCK4
2928/13 J 2444/13 2444/13 2444/13
1438/13 K BLANK 1883/13 BLANK
1104/14 L 2607/13 BLANK 2607/13
980/14     BLOCK5
95/14 M 0026/11 0026/11 0026/11
1998/14 N 2928/13 BLANK 2928/13
1428/14 O 1438/13 1438/13 BLANK
768/14     BLOCK6
P 1104/14 1104/14 1104/14
Q 980/14 980/14 BLANK
R 95/14 BLANK 95/14
   BLOCK7
S BLANK 1998/14 1998/14
T 1428/14 BLANK 1428/14
U 768/14 BLANK BLANK
ANNEXURE 2
      BLOCK1 1A1 1A2 1A3
1B1 BLANK 1B3
1C1 1C2 BLANK
             BLOCK2               2D1               2D2             2D3
              2 E1                2 E2            BLANK
              2F1                2F2             BLANK
               BLOCK3                3G1                3G2              3G3
               3H1             BLANK              3H3
            BLANK                 1I2               3I3
               BLOCK4                  4J1                   4J2                4J3
              BLANK                   4K2               BLANK
                 4L1                BLANK                 4L3        
                BLOCK5                  5M1                   5M2                  5M3
                 5N1                 BLANK                   5N3
                  5O1                    5O2                 BLANK
                 BLOCK6                   6P1                     6P2                    6P3
                  6Q1                      6Q2                  BLANK
                   6R1                    BLANK                     6R3
                BLOCK7                  BLANK                       7S2                      7S3
                   7T1                    BLANK                       7T3
                   7U1                     BLANK                   BLANK
